# Meadows R6 vs Marlborough SL

## FW

### 1NC Util

#### The standard should be preserving human life

#### Epistemic modesty breaks any tie and answers all AC pre-empts

Nick Bostrom, Existential Risk Prevention as a Global Priority, 2012. NS

These reflections on moral uncertainty suggest an alternative, complementary way of looking at existential risk. Let me elaborate. Our present understanding of axiology might well be confused. We may not now know—at least not in concrete detail—what outcomes would count as a big win for humanity; we might not even yet be able to imagine the best ends of our journey. If we are indeed profoundly uncertain about our ultimate aims, then we should recognize that there is a great option value in preserving—and ideally improving—our ability to recognize value and to steer the future accordingly. Ensuring that there will be a future version of humanity with great powers and a propensity to use them wisely is plausibly the best way available to us to increase the probability that the future will contain a lot of value.

#### Extinction justifies moral loopholes

Bok, 1988 (Sissela Bok, Professor of Philosophy, Brandeis, Applied Ethics and Ethical Theory, Ed. David Rosenthal and Fudlou Shehadi, 1988)

The same argument can be made for Kant’s other formulations of the Categorical Imperative: “So act as to use humanity, both in your own person and in the person of every other, always at the same time as an end, never simply as a means”; and “So act as if you were always through actions a law-making member in a universal Kingdom of Ends.” No one with a concern for humanity could consistently will to risk eliminating humanity in the person of himself and every other or to risk the death of all members in a universal Kingdom of Ends for the sake of justice. To risk their collective death for the sake of following one’s conscience would be, as Rawls said, “irrational, crazy.” And to say that one did not intend such a catastrophe, but that one merely failed to stop other persons from bringing it about would be beside the point when the end of the world was at stake.For although it is true that we cannot be held responsible for most of the wrongs that others commit, the Latin maxim presents a case where we would have to take such a responsibility seriously—perhaps to the point of deceiving, bribing, even killing an innocent person, in order that the world not perish.

#### Our Offense

#### 1. Science proves non util ethics are impossible and our version of util solves all aff offense

Greene 10 – Joshua, Associate Professor of Social science in the Department of Psychology at Harvard University

(The Secret Joke of Kant’s Soul published in Moral Psychology: Historical and Contemporary Readings, accessed: www.fed.cuhk.edu.hk/~lchang/material/Evolutionary/Developmental/Greene-KantSoul.pdf)

**What turn-of-the-millennium science** **is telling us is that human moral judgment is not a pristine rational enterprise**, that our **moral judgments are driven by a hodgepodge of emotional dispositions, which themselves were shaped by a hodgepodge of evolutionary forces, both biological and cultural**. **Because of this, it is exceedingly unlikely that there is any rationally coherent normative moral theory that can accommodate our moral intuitions**. Moreover, **anyone who claims to have such a theory**, or even part of one, **almost certainly doesn't**. Instead, what that person probably has is a moral rationalization. It seems then, that we have somehow crossed the infamous "is"-"ought" divide. How did this happen? Didn't Hume (Hume, 1978) and Moore (Moore, 1966) warn us against trying to derive an "ought" from and "is?" How did we go from descriptive scientific theories concerning moral psychology to skepticism about a whole class of normative moral theories? The answer is that we did not, as Hume and Moore anticipated, attempt to derive an "ought" from and "is." That is, our method has been inductive rather than deductive. We have inferred on the basis of the available evidence that the phenomenon of rationalist deontological philosophy is best explained as a rationalization of evolved emotional intuition (Harman, 1977). Missing the Deontological Point I suspect that **rationalist deontologists will remain unmoved by the arguments presented here**. Instead, I suspect, **they** **will insist that I have simply misunderstood what** Kant and like-minded **deontologists are all about**. **Deontology, they will say, isn't about this intuition or that intuition**. It's not defined by its normative differences with consequentialism. **Rather, deontology is about taking humanity seriously**. Above all else, it's about respect for persons. It's about treating others as fellow rational creatures rather than as mere objects, about acting for reasons rational beings can share. And so on (Korsgaard, 1996a; Korsgaard, 1996b). **This is, no doubt, how many deontologists see deontology. But this insider's view**, as I've suggested, **may be misleading**. **The problem**, more specifically, **is that it defines deontology in terms of values that are not distinctively deontological**, though they may appear to be from the inside. **Consider the following analogy with religion. When one asks a religious person to explain the essence of his religion, one often gets an answer like this: "It's about love**, really. It's about looking out for other people, looking beyond oneself. It's about community, being part of something larger than oneself." **This sort of answer accurately captures the phenomenology of many people's religion, but it's nevertheless inadequate for distinguishing religion from other things**. This is because many, if not most, non-religious people aspire to love deeply, look out for other people, avoid self-absorption, have a sense of a community, and be connected to things larger than themselves. In other words, secular humanists and atheists can assent to most of what many religious people think religion is all about. From a secular humanist's point of view, in contrast, what's distinctive about religion is its commitment to the existence of supernatural entities as well as formal religious institutions and doctrines. And they're right. These things really do distinguish religious from non-religious practices, though they may appear to be secondary to many people operating from within a religious point of view. In the same way, I believe that most of **the standard deontological/Kantian self-characterizatons fail to distinguish deontology from other approaches to ethics**. (See also Kagan (Kagan, 1997, pp. 70-78.) on the difficulty of defining deontology.) It seems to me that **consequentialists**, as much as anyone else, **have respect for persons**, **are against treating people as mere objects,** **wish to act for reasons that rational creatures can share, etc**. **A consequentialist respects other persons, and refrains from treating them as mere objects, by counting every person's well-being in the decision-making process**. **Likewise, a consequentialist attempts to act according to reasons that rational creatures can share by acting according to principles that give equal weight to everyone's interests, i.e. that are impartial**. This is not to say that consequentialists and deontologists don't differ. They do. It's just that the real differences may not be what deontologists often take them to be. What, then, distinguishes deontology from other kinds of moral thought? A good strategy for answering this question is to start with concrete disagreements between deontologists and others (such as consequentialists) and then work backward in search of deeper principles. This is what I've attempted to do with the trolley and footbridge cases, and other instances in which deontologists and consequentialists disagree. **If you ask a deontologically-minded person why it's wrong to push someone in front of speeding trolley in order to save five others, you will get** characteristically deontological **answers**. Some **will be tautological**: **"Because it's murder!"** **Others will be more sophisticated: "The ends don't justify the means**." "You have to respect people's rights." **But**, as we know, **these answers don't really explain anything**, because **if you give the same people** (on different occasions) **the trolley case** or the loop case (See above), **they'll make the opposite judgment**, even though their initial explanation concerning the footbridge case applies equally well to one or both of these cases. **Talk about rights, respect for persons, and reasons we can share are natural attempts to explain, in "cognitive" terms, what we feel when we find ourselves having emotionally driven intuitions that are odds with the cold calculus of consequentialism**. Although these explanations are inevitably incomplete, **there seems to be "something deeply right" about them because they give voice to powerful moral emotions**. **But, as with many religious people's accounts of what's essential to religion, they don't really explain what's distinctive about the philosophy in question**.

## Case

**Overreliance on vaccines hurts pandemic response at large**

**Lovelace 1/13** [Berkeley Lovelace Jr., health-care reporter for CNBC, mainly covering pharmaceuticals and the Food and Drug Administration. “WHO says Covid vaccines aren’t ‘silver bullets’ and relying entirely on them has hurt nations,” CNBC, 1-13-2021, accessed 8-11-2021, https://www.cnbc.com/2021/01/15/who-says-covid-vaccines-arent-silver-bullets-and-relying-entirely-on-them-has-hurt-nations.html] HWIC

The World Health Organization said Friday that [coronavirus](https://www.cnbc.com/2021/01/15/coronavirus-live-updates.html) vaccines aren’t “silver bullets” and relying solely on them to fight the pandemic has hurt nations. Some countries in Europe, Africa and the Americas are seeing spikes in Covid-19 cases “because we are collectively not succeeding at breaking the chains of transmission at the community level or within households,” WHO Director-General Tedros Adhanom Ghebreyesus said during a news conference from the agency’s Geneva headquarters. With [global deaths reaching 2 million](https://www.cnbc.com/2021/01/15/coronavirus-live-updates.html) and new variants of the virus appearing in multiple countries, world leaders need to do all they can to curb infections “through tried and tested public health measures,” Tedros said. “There is only one way out of this storm and that is to share the tools we have and commit to using them together.” The [coronavirus](https://www.cnbc.com/coronavirus/) has infected more than 93.3 million people worldwide and killed at least 2 million since the pandemic began about a year ago, according to data compiled by Johns Hopkins University. The virus continues to accelerate in some regions, with nations reporting that their supply of oxygen for Covid-19 patients is running “dangerously low,” the WHO said. Some countries, including the U.S., have focused heavily on the use of vaccines to combat their outbreaks. While vaccines are a useful tool, they will not end the pandemic alone, Mike Ryan, executive director of the WHO’s health emergencies program, said at the news conference. “We warned in 2020 that if we were to rely entirely on vaccines as the only solution, we could lose the very controlled measures that we had at our disposal at the time. And I think to some extent that has come true,” Ryan said, adding the colder seasons and the recent holidays also may have also played a role in the spread of the virus. “A big portion of the transmission has occurred because we are reducing our physical distancing. ... We are not breaking the chains of transmission. The virus is exploiting our lack of tactical commitment,” he added. “We are not doing as well as we could.” Dr. Bruce Aylward, a senior advisor to the WHO’s director-general, echoed Ryan’s comments, saying, vaccines are not “silver bullets” “Things can get worse, numbers can go up,” he said. We have vaccines, yes. But we have limited supplies of vaccines that will be rolled out slowly across the world. And vaccines are not perfect. They don’t protect everyone against every situation.” In the U.S., the pace of vaccinations is going slower than officials had hoped. As of Friday at 6 a.m. ET, more than 31.1 million doses of vaccine had been distributed across the U.S., but just over 12.2 million shots have been administered, according to data compiled by the Centers for Disease Control and Prevention. Meanwhile, cases are rapidly growing, with the U.S. recording at least 238,800 new Covid-19 cases and at least 3,310 virus-related deaths each day, based on a seven-day average calculated by CNBC using Johns Hopkins data. On Thursday, President-elect Joe Biden [unveiled a sweeping plan](https://www.cnbc.com/2021/01/14/biden-unveils-sweeping-plan-to-combat-the-covid-pandemic-in-the-us.html) to combat the coronavirus pandemic in the United States. While his administration will invest billions in a vaccine campaign, it will also scale up testing, invest in new treatments and work to identify new strains, among other measures.

#### IP protections don’t cause disease spread because patent incidence is low and independently increases access- prefer empirics.

Stevens 04 [Philip Stevens, Director of Health Projects at the International Policy Network. “Diseases of poverty and the 10/90 Gap.” November 2004. <https://www.who.int/intellectualproperty/submissions/InternationalPolicyNetwork.pdf>] AL

Much debate on this issue of access has centred around the claim that patents held by pharmaceutical companies are a significant contributor to the dire health outcomes experienced by people in the poorest parts of the world. This claim is based on the premise that pharmaceutical companies use their patents to withhold drugs from poorer people in order to maximise their profits. However, **this premise is false.** A study by Amir Attaran has shown that in 65 low- and middleincome countries, where four billion people live, **patenting is rare for the 319 products** on the World Health Organisation’s Model List of Essential Medicines. Only seventeen essential medicines on the list are on patent in any of the countries, so that **overall patent incidence is low (1.4 percent)** and concentrated in larger markets. Those drugs on patent include 12 antiretrovirals and one antifungal, with most of those ARVs belonging to one company.30 Furthermore, **many companies choose not to enforce their patents** in certain lower-income countries. Of the 969 cases surveyed by Attaran where companies probably could have obtained and maintained patents for these essential medicines, they did so only 31 per cent of the time. However, intellectual property rights (IPR) are still important factor in ensuring access to essential medicines. Without IPR, it is **unlikely that sufficient incentives would have existed to develop many of the 319 products on the WHO’s essential medicines list in the first place.** This is substantiated by the fact that 90 per cent of the products on the list were originally discovered and/or developed by private companies.31

#### Reducing IP rights aren’t quick enough to help the pandemic – legal battles slow the process – experts agree

Smith 05/05

(Laura Smith-Spark; Newsdesk Editor, CNN Digital; (05-05-21) Rich nations urged to share vaccine knowledge while WTO debates waiving patents; CNN; <https://www.cnn.com/2021/05/05/world/covid-19-vaccine-patents-wto-intl/index.html>; CKD)

But even as public pressure grows, some experts argue that handing over the IP rights for Covid-19 vaccines won't necessarily mean that more can be rapidly produced worldwide at large scale. US infectious diseases chief Anthony Fauci [told the UK's Financial Times](https://www.ft.com/content/2f41b122-5738-4707-a822-0d79276710c5) on Monday that he was not convinced that forcing companies to share their intellectual property was the most effective approach, warning that legal battles could slow the process. "Going back and forth, consuming time and lawyers in a legal argument about waivers -- that is not the endgame. People are dying around the world and we have to get vaccines into their arms in the fastest and most efficient way possible," he said.

#### Negotiations on a waiver will take too long

Mercurio 06-24

(Bryan Mercurio; Law Prof. at The Chinese University of Hong Kong; (06-24-21) The IP Waiver for COVID-19: Bad Policy, Bad Precedent; IIC on Springer Link; <https://link.springer.com/article/10.1007/s40319-021-01083-5>; CKD)

On 5 May 2021, the US reversed its position and announced that it would support a waiver for COVID-19 vaccines.[Footnote6](https://link.springer.com/article/10.1007/s40319-021-01083-5#Fn6) To be clear, this does not mean that the US supported the waiver as proposed by India and South Africa. Instead, the US has simply agreed to negotiate the perimeters of a waiver. Others, including the European Union (EU), Canada, Australia, Norway, Switzerland, the United Kingdom (UK) and even leading developing countries such as Brazil, Chile and Mexico remain opposed or lukewarm on the waiver.[Footnote7](https://link.springer.com/article/10.1007/s40319-021-01083-5#Fn7) The US dropping opposition does not mean the concerns of other Members will simply disappear – one would hope that these nations opposed the waiver for valid reasons and did not simply blindly follow the US. Indeed, many of the above-listed Members remain unconvinced that even such a draconian step as a waiver of IPRs would accomplish the goal of increased vaccine production.[Footnote8](https://link.springer.com/article/10.1007/s40319-021-01083-5#Fn8) For its part, the EU continues to favour an approach which makes better use of existing flexibilities available in the TRIPS Agreement.[Footnote9](https://link.springer.com/article/10.1007/s40319-021-01083-5#Fn9) Thus, those expecting quick agreement on the waiver will be disappointed. Negotiations at the WTO are always difficult and lengthy, and US Trade Representative Katherine Tai acknowledged that the “negotiations will take time given the consensus-based nature of the institution and the complexity of the issues involved”.[Footnote10](https://link.springer.com/article/10.1007/s40319-021-01083-5#Fn10) Issues of negotiation will include the scope of the waiver. Whereas the original proposal and its amended form extend the waiver beyond patents and vaccines to include nearly all forms of IP (i.e. copyright,[Footnote11](https://link.springer.com/article/10.1007/s40319-021-01083-5#Fn11) industrial designs and trade secrets) as well as to all “health products and technologies including diagnostics, therapeutics, vaccines, medical devices, personal protective equipment, their materials or components, and their methods and means of manufacture for the prevention, treatment or containment of COVID-19”[Footnote12](https://link.springer.com/article/10.1007/s40319-021-01083-5#Fn12) (with no requirement on how or the extent to which they are related to or useful in combatting COVID-19), the US and others seem to support a waiver limited to patents and vaccines.[Footnote13](https://link.springer.com/article/10.1007/s40319-021-01083-5#Fn13) The length of the waiver will also be a contentious negotiating issue, with proponents seeking a virtual indefinite waiver lasting until the Membership agrees by consensus that it is no longer required – meaning even a single Member’s objection to ending the waiver would mean the waiver continues to remain in force[Footnote14](https://link.springer.com/article/10.1007/s40319-021-01083-5#Fn14) – as will the request that any action claimed to be taken under the waiver is outside the scope of the WTO’s dispute settlement mechanism.[Footnote15](https://link.springer.com/article/10.1007/s40319-021-01083-5#Fn15) These provisions will almost certainly be opposed by other Members, who would perhaps agree to a time-limited waiver which could be extended rather than an unchallengeable indefinite waiver which will be difficult to reverse. The proposal also fails to mention anything in relation to transparency and notification requirements and lacks safeguards against abuse or diversion. These points will likely also prove contentious in the negotiations. With so many initial divergences and as yet undiscussed issues, the negotiations at best could be completed by the time of the next WTO Ministerial Conference, scheduled to begin on 20 November 2021. There is precedent in this regard, as previous TRIPS negotiations involving IP and pharmaceuticals were not fully resolved until the days before the Ministerial Conferences (in 2003 and 2005).[Footnote16](https://link.springer.com/article/10.1007/s40319-021-01083-5#Fn16) There is also a chance that the negotiations will continue past the calendar year 2021. The chance for a swift negotiation diminished with the release of a revised proposal by India and South Africa on 22 May 2021. As mentioned above, the proposal contains no limit as to product coverage, scope, notification requirements or safeguards and proposes that the waiver will remain in effect for what could be an indefinite period. This was not a proposal designed to engender quick negotiations and a solution. Instead, the proposal perhaps reveals India’s and South Africa’s true intent to use the COVID-19 pandemic as an excuse to roll-back IPRs rather than a good-faith effort to rapidly increase access to lifesaving vaccines and treatments around the world.

#### Equitable distribution of vaccines can’t combat disease spread because of other barriers like vaccine uptake, effectiveness, durability, eligibility factors, logistical problems, and mutations- ignore aff’s myopic promotions

MacLeod 2-10 [Iain MacLeod, co-founder and CEO of Aldatu Biosciences of Watertown, Massachusetts, which develops novel viral diagnostics, including those for pathogens such as SARS-CoV-2, and a research associate at the Harvard T.H. Chan School of Public Health. “Do the math: Vaccines alone won’t get us out of this pandemic.” February 10, 2021. <https://www.statnews.com/2021/02/10/vaccines-alone-wont-end-pandemic/>] AL

But it seems as if there is light at the end of the tunnel. As long as we maintain social distancing, keep wearing masks, and washing our hands, it feels to many as though we can hold on until we get vaccinated. I’m sorry to be writing the words that follow, but here they are: We can’t vaccinate our way out of this pandemic. And the myopic focus on achieving herd immunity through mass vaccination may even make it tougher for America — and the world — to defeat Covid-19. Don’t get me wrong: Mass vaccination is essential. But herd immunity is a numbers game. It is defined as the point at which community spread of a disease stops because unprotected individuals are surrounded by a “herd” of people who are immune to infection, making it difficult, if not impossible, for infected people to pass on the disease. Many experts have said we will achieve herd immunity when about 70% of the population is immune to SARS-CoV-2, the virus that causes Covid-19, either through vaccination or by having had Covid-19. How do we reach that number? It’s harder than it seems. For starters, while the Pfizer/BioNTech and Moderna vaccines showed about 95% efficacy in the clinical trials, **vaccine effectiveness** — how well a vaccine performs under real-world conditions — is likely to be lower for several reasons. One is that the people who participate in clinical trials are an imperfect representation of the whole population. They tend to be healthier, and younger. Real-world factors such as vaccine transportation and storage can also reduce vaccine effectiveness. Say the Moderna and Pfizer vaccines now being given across the country achieve 90% effectiveness. Vaccinating 70% of U.S. residents puts us at 63% immunity. So, we’ll need to vaccinate a full 80% of the population to reach the herd immunity threshold. **Additional vaccines are starting to be approved. Some of them have lower efficacy.** For instance, the AstraZeneca vaccine has about 70% efficacy, and Johnson & Johnson has reported that its one-dose vaccine has 66% efficacy. Their real-world performance could be lower still. If these vaccines become part of the mix in the U.S., actual protection will be lower than the estimated 90% we’d get from just the Moderna and Pfizer vaccines. There are other barriers to achieving herd immunity. Vaccine uptake — how many people actually get vaccinated — is far below the level we need, in part because Covid-19 beliefs have been politicized in the U.S. and a percentage of the population doesn’t even believe the disease is real. In a Kaiser Health News survey released near the end of January, 13% of Americans said they would “definitely not” get vaccinated, 7% would take the vaccine only if it was “required,” and another 31% would “wait and see how it’s working” before getting vaccinated. Not encouraging numbers for those hoping for a quick journey to herd immunity. Even when ample vaccine supplies are restored — perhaps by President Biden invoking the Defense Production Act — other factors will further drive down the number of people who get vaccinated. Eligibility factors currently exclude approximately 25% of U.S. residents from Covid-19 vaccination. The Pfizer vaccine can be administered only to those age 16 and up; for the Moderna vaccine, it’s those 18 and up. This represents approximately 20% of the population. Furthermore, although the CDC says that pregnant people may get vaccinated, it stops short of a clear recommendation. The decision is a “personal choice” left up to individuals and their health care providers. Excluding those currently ineligible for vaccination against SARS-CoV-2 due to age or other conditions leaves 75% of Americans with no restrictions on vaccination. Factoring in the 13% of Americans who definitely don’t want the vaccine and the 7% who would get it only if it was required means just 49.5% of Americans would have immunity in the near future. If half of those who are in a wait-and-see mode don’t get vaccinated — another 15% of the population — then we are looking at just 40% vaccine coverage of the currently eligible population, far below the 70% needed for herd immunity. And that’s even before considering that real-world vaccine effectiveness will be below clinical trial levels. The young people who aren’t cleared to get the Moderna and Pfizer vaccines have proven to be highly efficient asymptomatic spreaders of Covid-19. Leaving this population unprotected will enable the disease to continue to spread widely. Finally, we don’t yet know the durability of the immune response to the various vaccines. It may persist. Or it may wear off, leaving people vulnerable after they’ve been vaccinated and creating conditions for new outbreaks. If my years of global health work on the HIV/AIDS epidemic has taught me anything, it’s that even the best laid plans can’t anticipate every challenge. To vaccinate 75% of the U.S. population, approximately 248 million people — that’s nearly 500 million doses — are needed. And it means we need to be vaccinating nearly 2 million people a day so all of them are immune by the fall of 2021. As I write this, we’re vaccinating only about 1 million people a day. At that pace, Reuters estimates it would take until April 2022 for 75% of Americans to receive at least their first vaccine dose. And that’s only if everything goes well logistically (it won’t) and if there are no further mutations in SARS-CoV-2 that make combating it more difficult (there will be). It’s time to stop promoting the myopic belief that the unrealistic goal of herd immunity can be achieved in 2021 and start looking to reinforcing all aspects of the health care response as we start to concede that Covid-19 will become an endemic disease that will continue to lurk in the population. For the foreseeable future, that means continued physical distancing; occupancy limits in restaurants and other retail establishments; replacement of physical menus with smart phone-based menus to prevent surface spread of the virus, and more. We’ll also need to monitor people who have been vaccinated to gauge the durability of the immune system’s response and whether booster shots are necessary, as they are for tetanus and diphtheria. Finally, our nation’s public health infrastructure will need to be bolstered, putting in place new protocols to monitor for new variants of the virus as soon as they emerge. Can we defeat Covid-19? We can and we will. But setting sights on a near-term goal of achieving herd immunity ignores the math that governs the spread of disease. That approach is going to take a while. To get past Covid-19, we need to use all the tools available.

## 1

**1. Pharma profits are up from COVID vaccines, patent waivers threaten this**

**Buchholz 5-17-21**

(Katharina, https://www.statista.com/chart/24829/net-income-profit-pharma-companies/)

The profitability of coronavirus vaccines has been in the spotlight since U.S. President Joe Biden come out in support of temporarily lifting vaccine patents to make the production of the life-saving inoculations more financially feasible for poorer countries. EU leaders meanwhile remain divided over such a move. Company financial reports show that COVID-19 vaccine makers and developers like Johnson & Johnson, Pfizer, Moderna, AstraZeneca and BioNTech have seen their profits increase since the vaccine rollout, at times majorly. In early May, stocks of several companies that benefit from COVID-19 vaccine sales **took a nosedive on the news of Biden’s reversal**. Moderna stocks, for example, were still down more than 6 percent at close on May 5, the day of the announcement. Stocks recovered somewhat as German chancellor Angela Merkel came out against patent waivers the following day. While fluctuations in the stock market price have hurt drug makers in the **short term**, patent waivers would diminish the bottom line of companies involved with the development and production of COVID-19 **vaccines in the long term**. Pharma giants like Johnson & Johnson and Pfizer bring in billions of dollars of income every quarter from diverse sources, so the COVID bump was smaller for them. In the case of Pfizer, which has been a bigger producer than J&J, the year-over-year profit increase was a handsome 44 percent, however. For smaller AstraZeneca, the COVID year meant that its profits doubled. In the case of Moderna, the past year has turned a Q1 loss into a profit. The case is similar for German company BioNTech, which collaborated with Pfizer on its COVID vaccine. While Q1 2021 brought in a profit of $1.1 billion, the company ran a deficit since its founding in 2008 up until Q4 2020, when it posted a profit for the first time. The $446 million earned stood in contrast to losses of almost $428 million accrued in the first nine months of the year.

**2. Strong IP protection spurs innovation by encouraging risk-taking and incentivizing knowledge sharing -- prefer statistical analysis of multiple studies**

**Ezell and Cory 19** [Stephen Ezell, vice president & global innovation policy @ ITIF, BS Georgetown School of Foreign Service. Nigel Cory, associate director covering trade policy @ ITIF, MA public policy @ Georgetown. "The Way Forward for Intellectual Property Internationally," Information Technology & Innovation Foundation, 4-25-2019, accessed 8-25-2021, https://itif.org/publications/2019/04/25/way-forward-intellectual-property-internationally] HWIC

IPRs Strengthen Innovation

Intellectual property rights power innovation. For instance, analyzing the level of intellectual property protections (via the World Economic Forum’s Global Competitiveness reports) and creative outputs (via the Global Innovation Index) shows that counties with stronger IP protection have more creative outputs (in terms of intangible assets and creative goods and services in a nation’s media, printing and publishing, and entertainment industries, including online), even at varying levels of development.46

IPR reforms also introduce strong incentives for domestic innovation. Sherwood, using case studies from 18 developing countries, concluded that poor provision of intellectual property rights deters local innovation and risk-taking.47 In contrast, IPR reform has been associated with increased innovative activity, as measured by domestic patent filings, albeit with some variation across countries and sectors.48 For example, Ryan, in a study of biomedical innovations and patent reform in Brazil, found that patents provided incentives for innovation investments and facilitated the functioning of technology markets.49 Park and Lippoldt also observed that the provision of adequate protection for IPRs can help to stimulate local innovation, in some cases building on the transfer of technologies that provide inputs and spillovers.50 In other words, local innovators are introduced to technologies first through the technology transfer that takes place in an environment wherein protection of IPRs is assured; then, they may build on those ideas to create an evolved product or develop alternate approaches (i.e., to innovate). Related research finds that trade in technology—through channels including imports, foreign direct investment, and technology licensing—improves the quality of developing-country innovation by increasing the pool of ideas and efficiency of innovation by encouraging the division of innovative labor and specialization.51 However, Maskus notes that without protection from potential abuse of their newly developed technologies, foreign enterprises may be less willing to reveal technical information associated with their innovations.52 The protection of patents and trade secrets provides necessary legal assurances for firms wishing to reveal proprietary characteristics of technologies to subsidiaries and licensees via contracts.

Counties with stronger IP protection have more creative outputs (in terms of intangible assets and creative goods and services in a nation’s media, printing and publishing, and entertainment industries, including online), even at varying levels of development.

The relationship between IPR rights and innovation can also be seen in studies of how the introduction of stronger IPR laws, with regard to patents, copyrights, and trademarks, affect R&D activity in an economy. Studies by Varsakelis and by Kanwar and Evenson found that R&D to GDP ratios are positively related to the strength of patent rights, and are conditional on other factors.53 Cavazos Cepeda et al. found a positive influence of IPRs on the level of R&D in an economy, with each 1 percent increase in the level of protection of IPRs in an economy (as measured by improvements to a country’s score in the Patent Rights Index) equating to, on average, a 0.7 percent increase in the domestic level of R&D.54 Likewise, a 1 percent increase in copyright protection was associated with a 3.3 percent increase in domestic R&D. Similarly, when trademark protection increased by 1 percent, there was an associated R&D increase of 1.4 percent. As the authors concluded, “Increases in the protection of the IPRs carried economic benefits in the form of higher inflows of FDI, and increases in the levels of both domestically conducted R&D and service imports as measured by licensing fees.”55 As Jackson summarized, regarding the relationship between IPR reform and both innovation and R&D, and FDI, “In addition to spurring domestic innovation, strong intellectual property rights can increase incentives for foreign direct investment which in turn also leads to economic growth.”56

**3. Biopharmaceutical innovation is key to prevent future pandemics and bioterror**

**Marjanovic and Feijao 20** [Sonja Marjanovic Ph.D., Judge Business School, University of Cambridge. Carolina Feijao, Ph.D. in biochemistry, University of Cambridge; M.Sc. in quantitative biology, Imperial College London; B.Sc. in biology, University of Lisbon. "How to Best Enable Pharma Innovation Beyond the COVID-19 Crisis," RAND Corporation, 05-2020, accessed 8-8-2021, https://www.rand.org/pubs/perspectives/PEA407-1.html] HWIC

As key actors in the healthcare innovation landscape, pharmaceutical and life sciences companies have been called on to develop medicines, vaccines and diagnostics for pressing public health challenges. The COVID-19 crisis is one such challenge, but there are many others. For example, MERS, SARS, Ebola, Zika and avian and swine flu are also infectious diseases that represent public health threats. Infectious agents such as anthrax, smallpox and tularemia could present threats in a bioterrorism context.1 The general threat to public health that is posed by antimicrobial resistance is also well-recognised as an area in need of pharmaceutical innovation. Innovating in response to these challenges does not always align well with pharmaceutical industry commercial models, shareholder expectations and competition within the industry. However, the expertise, networks and infrastructure that industry has within its reach, as well as public expectations and the moral imperative, make pharmaceutical companies and the wider life sciences sector an indispensable partner in the search for solutions that save lives. This perspective argues for the need to establish more sustainable and scalable ways of incentivising pharmaceutical innovation in response to infectious disease threats to public health. It considers both past and current examples of efforts to mobilise pharmaceutical innovation in high commercial risk areas, including in the context of current efforts to respond to the COVID-19 pandemic. In global pandemic crises like COVID-19, the urgency and scale of the crisis – as well as the spotlight placed on pharmaceutical companies – mean that contributing to the search for effective medicines, vaccines or diagnostics is essential for socially responsible companies in the sector. 2 It is therefore unsurprising that we are seeing industry-wide efforts unfold at unprecedented scale and pace. Whereas there is always scope for more activity, industry is currently contributing in a variety of ways. Examples include pharmaceutical companies donating existing compounds to assess their utility in the fight against COVID19; screening existing compound libraries in-house or with partners to see if they can be repurposed; accelerating trials for potentially effective medicine or vaccine candidates; and in some cases rapidly accelerating in-house research and development to discover new treatments or vaccine agents and develop diagnostics tests.3,4 Pharmaceutical companies are collaborating with each other in some of these efforts and participating in global R&D partnerships (such as the Innovative Medicines Initiative effort to accelerate the development of potential therapies for COVID-19) and supporting national efforts to expand diagnosis and testing capacity and ensure affordable and ready access to potential solutions.3,5,6 The primary purpose of such innovation is to benefit patients and wider population health. Although there are also reputational benefits from involvement that can be realised across the industry, there are likely to be relatively few companies that are ‘commercial’ winners. Those who might gain substantial revenues will be under pressure not to be seen as profiting from the pandemic. In the United Kingdom for example, GSK has stated that it does not expect to profit from its COVID-19 related activities and that any gains will be invested in supporting research and long-term pandemic preparedness, as well as in developing products that would be affordable in the world’s poorest countries.7 Similarly, in the United States AbbVie has waived intellectual property rights for an existing combination product that is being tested for therapeutic potential against COVID-19, which would support affordability and allow for a supply of generics.8,9 Johnson & Johnson has stated that its potential vaccine – which is expected to begin trials – will be available on a not-for-profit basis during the pandemic.10 Pharma is mobilising substantial efforts to rise to the COVID-19 challenge at hand. However, we need to consider how pharmaceutical innovation for responding to emerging infectious diseases can best be enabled beyond the current crisis. Many public health threats (including those associated with other infectious diseases, bioterrorism agents and antimicrobial resistance) are urgently in need of pharmaceutical innovation, even if their impacts are not as visible to society as COVID-19 is in the immediate term. The pharmaceutical industry has responded to previous public health emergencies associated with infectious disease in recent times – for example those associated with Ebola and Zika outbreaks.11 However, it has done so to a lesser scale than for COVID-19 and with contributions from fewer companies. Similarly, levels of activity in response to the threat of antimicrobial resistance are still low.12 There are important policy questions as to whether – and how – industry could engage with such public health threats to an even greater extent under improved innovation conditions.

**4. That causes extinction, which outweighs.**

**Millett & Snyder-Beattie ‘17**. Millett, Ph.D., Senior Research Fellow, Future of Humanity Institute, University of Oxford; and Snyder-Beattie, M.S., Director of Research, Future of Humanity Institute, University of Oxford. 08-01-2017. “Existential Risk and Cost-Effective Biosecurity,” Health Security, 15(4), PubMed

In the decades to come, advanced bioweapons could **threaten human existence**. Although the **probability** of human extinction from bioweapons **may** be low, the **expected value** of **reducing** the risk could **still** be **large**, since such risks jeopardize the existence of **all future generations**. We provide an overview of biotechnological extinction risk, make some rough initial estimates for how severe the risks might be, and compare the cost-effectiveness of reducing these extinction-level risks with existing biosecurity work. We find that reducing human extinction risk can be more cost-effective than reducing smaller-scale risks, even when using conservative estimates. This suggests that the risks are not low enough to ignore and that more ought to be done to prevent the worst-case scenarios. How worthwhile is it spending resources to study and mitigate the chance of human extinction from biological risks? The risks of such a catastrophe are presumably low, so a skeptic might argue that addressing such risks would be a waste of scarce resources. In this article, we investigate this position using a cost-effectiveness approach and ultimately conclude that the expected value of reducing these risks is large, especially since such risks jeopardize the existence of all future human lives. **Historically, disease events have been responsible for the greatest death tolls** on humanity. The 1918 flu was responsible for more than 50 million deaths,1 while smallpox killed perhaps 10 times that many in the 20th century alone.2 The Black Death was responsible for killing over 25% of the European population,3 while other pandemics, such as the plague of Justinian, are thought to have killed 25 million in the 6th century—constituting over 10% of the world's population at the time.4 It is an open question whether a future pandemic could result in outright human extinction or the irreversible collapse of civilization. A skeptic would have many good reasons to think that existential risk from disease is unlikely. Such a disease would need to spread worldwide to **remote populations**, overcome **rare genetic resistances**, and **evade detection**, cures, and **countermeasures**. Even evolution itself may work in humanity's favor: **Virulence and transmission is often a trade-off**, and so **evolutionary pressures** could push against maximally lethal wild-type pathogens.5,6 While these arguments point to a very small risk of human extinction, they **do not rule** the possibility **out** entirely. Although rare, there are recorded instances of **species going extinct due to disease**—primarily in amphibians, but also in 1 mammalian species of rat on Christmas Island.7,8 **There are** also **historical examples of large human populations being almost entirely wiped out** by disease, especially when multiple diseases were simultaneously introduced into a population without immunity. The most striking examples of total population collapse include **native American tribes** exposed to European diseases, such as the Massachusett (86% loss of population), Quiripi-Unquachog (95% loss of population), and the Western Abenaki (which suffered a staggering 98% loss of population).9 In the modern context, no single disease currently exists that combines the worst-case levels of transmissibility, lethality, resistance to countermeasures, and global reach. But **many diseases are proof** of principle that **each worst-case attribute can be realized independently**. For example, some diseases exhibit nearly a 100% case fatality ratio in the absence of treatment, such as rabies or septicemic plague. Other diseases have a track record of spreading to virtually every human community worldwide, such as the 1918 flu,10 and seroprevalence studies indicate that other pathogens, such as chickenpox and HSV-1, can successfully reach over 95% of a population.11,12 Under optimal virulence theory, **natural evolution** would be an **unlikely** source for pathogens with the **highest possible levels of transmissibility, virulence, and global reach**. But **advances in biotech**nology might allow the creation of diseases that **combine such traits**. Recent controversy has **already emerged** over a number of **scientific experiments** that resulted in viruses with enhanced **transmissibility**, **lethality**, and/or the ability to overcome **therapeutics**.13-17 Other experiments demonstrated that mousepox could be modified to have a 100% case fatality rate and render a vaccine ineffective.18 In addition to transmissibility and lethality, studies have shown that other disease traits, such as incubation time, environmental survival, and available vectors, could be modified as well.19-21 Although these experiments had scientific merit and were not conducted with malicious intent, their implications are still worrying. This is especially true given that there is also a **long historical track record** of**state-run bioweapon research** applying cutting-edge science and technology to design agents not previously seen in nature. The Soviet bioweapons program developed agents with traits such as enhanced virulence, resistance to therapies, greater environmental resilience, increased difficulty to diagnose or treat, and which caused unexpected disease presentations and outcomes.22 Delivery capabilities have also been subject to the cutting edge of technical development, with Canadian, US, and UK bioweapon efforts playing a critical role in developing the discipline of aerobiology.23,24 While there is no evidence of state-run bioweapons programs directly attempting to develop or deploy bioweapons that would pose an existential risk, the logic of deterrence and **m**utually **a**ssured **d**estruction could create such incentives in more unstable political environments or following a breakdown of the Biological Weapons Convention.25 The **possibility of a war** between great powers could also increase the pressure to use such weapons—during the World Wars, bioweapons were used across multiple continents, with Germany targeting animals in WWI,26 and Japan using plague to cause an epidemic in China during WWII.27

## 2

#### 1. The plan’s reduction of IP is in line with a broader strategy of vaccine diplomacy – this treats global health as a game of political football to advance imperialist interests in the long-term – only anti-capitalist organizing solves.

Patanè, 21

[Andrea, writer for the IMT: “COVID-19 pandemic: patents and profits,” In Defence of Marxism, published 5-15-2021. https://www.marxist.com/covid-19-pandemic-patents-and-profits.htm]//AD

We are 16 months into a pandemic that according to some reports has claimed 6.9m lives and plunged capitalism into its deepest-ever crisis, and the ruling class is still torn by internecine squabbles over patent waivers, export bans and priority-deals. New rifts have opened up between sections of the bourgeoisie following the recent announcement that US president Joe Biden’s administration now supports “negotiations” on waiving COVID-19 vaccine patents. This is much to the consternation of the Big Pharma parasites, who are pocketing tens of billions of dollars thanks to their exclusive ownership of COVID-19 vaccines and other drugs. Again and again, we find proof that capitalism, a system based on narrow national interests and the pursuit of private profits is utterly unfit for purpose. Indeed, as a recent WHO-led investigation just confirmed, the entire pandemic was preventable. The market and bourgeois politicians brought about this disaster, and are utterly failing to resolve it. IP and Big Pharma profits In October last year, faced with the prospect of global vaccine shortages and the inability of poorer countries to acquire them, India and South Africa presented to the World Trade Organization a request to waive intellectual property rights on all the COVID-19-related drugs and technologies. This would allow the manufacture of cheap, generic versions anywhere in the world. Vaccines and medical technologies fall under the WTO agreements on Trade-Related Intellectual Property Rights, known as TRIPS, which protects the IP of the major pharmaceutical companies. According to one report, a TRIPS waiver could help in vaccinating more than 60 percent of the world population by the end of the year. Everyone on earth could be fully vaccinated by the end of 2022. The pandemic nightmare that billions of people are living through could be over once and for all. Surely then, a TRIPS waiver sounds like a sensible and necessary request? Especially given that the likes of Pfizer, Johnson & Johnson and AstraZeneca have already racked up profits of more than $26bn during the pandemic. What was being demanded was not too radical either: a one time temporary waiver on intellectual property rights related to just one vaccine. Also, the 2001 Doha Declaration on TRIPS and Public Health – agreed by all WTO states – maintains that public health should take precedence over the enforcement of IP rights. Unfortunately, Big Pharma takes a very different view, and isn’t going to let a trivial thing like the Doha Declaration undermine its private claim to COVID-19 vaccines. From their point of view, any concession in this particular case would set a very dangerous precedent. The IP protections afforded to Big Pharma are denying huge swathes of the world population access to vaccines, compounded by the vaccine nationalism of rich countries, which can afford to pay suppliers directly and are gobbling up global supplies. As, Dr. Tedros – the general director of WHO – has warned in the NYT that, following the current trajectory of vaccinations: “[w]e face the very real possibility of affluent countries administering variant-blocking boosters to already vaccinated people when many countries will still be scrounging for enough vaccines to cover their most-at-risk groups”. This is quite an appealing prospect for the Big Pharma bloodsuckers: namely, COVID-19 going endemic, much like a seasonal flu. With new variants breeding out of control in poor countries every year, and seasonal vaccines developed and distributed for those who can pay, billions of dollars would continue to flow in the pockets of these leeches, potentially for the years to come. Moderna CEO Stephane Bancel has already tempted his shareholders with such a “business model” – and is now projecting more than $19.2 billion in sales for this year! However, this bonanza depends on Big Pharma keeping a firm hold on its vaccine IP. Hundreds of thousands of people dying every single year as a result of COVID-19 going endemic is a very minor concern. Unsurprisingly then, Big Pharma has been lobbying governments world over against the TRIPS waiver. Up until now, they have been successful. As of October 2020, the US and EU not only opposed the waiver, but blocked the possibility of any discussion of it from taking place at WTO meetings. Now – after a criminal seven-month period in which hundreds of thousands of people have lost their lives to preventable second and third COVID-19 waves – Biden’s administration has come out in support of entering into negotiations over the TRIPS waiver. Unsurprisingly, Big Pharma reacted to this announcement with dismay. Pfizer CEO Albert Bourla argued that an IP waiver would “disrupt the flow of raw materials” for the vaccine production chain. One suspects he means Big Pharma’s exclusive control over these raw materials will be disrupted. Meanwhile, Johnson & Johnson called the waiver proposal “an unprecedented step that will undermine our global response to the pandemic and compromise safety”, by allowing poor countries to produce vaccines. This is despite the fact that India produces the highest number of vaccines in the world, and was one of the two countries that proposed the waiver in the first place. Big Pharma companies also complained that an IP-waiver would hand the likes of China access to Western-produced mRNA technologies, which aside from vaccine production, could be repurposed for, among other things, cancer research (quelle horreur!). Let us not forget that mRNA technology was developed in publicly-funded university research facilities in the first place, before it was appropriated by private companies. This is simply an argument for the latest developments in medical science being freely available to the entire world, rather than the private property of this or that capitalist regime. A “calculated risk” Far from an act of ‘international solidarity', this latest move from the US government is a calculated political risk, and will be implemented in the interests of US imperialism. A section of the more serious wing of the bourgeoisie understands that a proper economic recovery can happen only if the pandemic is suppressed worldwide. As we have explained elsewhere, wealthy countries risk losing billions of dollars if the pandemic is brought under control only within their own borders, because new variants (like those in India and Brazil) can always mutate elsewhere and reinfect their populations, causing further economic disruption. Therefore, even on a capitalist basis, it is expedient in the long-term for the rich countries to facilitate a global vaccination campaign. Even Pope Francis anointed the demand from his seat in Rome! Biden’s announcement is also an act of vaccine diplomacy. America’s main rivals, China and Russia, have been shoring up their spheres of influence by distributing their Sinopharm and Sputnik V vaccines to poor countries left out by the vaccine nationalism of the US and Europe. Chinese and Russian vaccines have been exported into countries traditionally under western spheres of influence, including Brazil and Hungary. Pushing to waive IP protections on COVID-19 vaccines is therefore partly an effort to push back against the encroachment of rival imperialist powers, which have so far outcompeted Washington in the global vaccination drive. Biden’s announcement is also an attempt to restore the standing and authority of US imperialism on the world stage, which has been bruised by the ‘America First’ vaccine nationalist policy started by Donald Trump, and continued by Biden. According to the FT, Katherine Tai (top US trade envoy) and Jake Sullivan (national security adviser) made the case to Biden that pushing for the waiver “was a low-risk way to secure a diplomatic victory”, after coming under fire for not “respond[ing] quickly enough to the unfolding COVID-19 crisis in India”. Here you have it, straight from the horse’s mouth. Under capitalism, vaccines – rather than providing a way out of the pandemic – are tools for ‘low-risk diplomatic victories’. As if this was some sort of football match between world leaders! In short, Biden is stepping in to prioritise the interests of US imperialism as a whole over the immediate interests of the Big Pharma capitalists. But we should say clearly: this cynical attempt to claim the moral high ground came only after the US used its massive economic clout to secure enough vaccines to inoculate its own population several times over. And in fact, the wartime Defense Production Act is still in effect, which forces US manufacturers to fulfil domestic demands for medical equipment before exports are permitted. This de facto export ban has created bottlenecks in the supply chain that have already undermined the WHO-led COVAX programme to vaccinate poor countries. Rest assured, Biden’s policy remains ‘America First’, just by somewhat more calculated means than his predecessor. Protectionist EU Meanwhile, in the Eurozone, where vaccine shortages still abound, EU leaders fired back at Biden that he should lift his export ban and give up some of America’s surplus supply before talking about waiving IP protections. President Emmanuel Macron in France said he favoured waiving vaccine IP in principle, but that this was a lower priority than the US and Britain ending export bans on resources and giving up their spare vaccines. “If we want to work quickly, today there isn’t one factory in the world that can’t produce doses for poor countries because of intellectual property,” Macron said on the weekend. “The priority today is not intellectual property – it’s not true. We would be lying to ourselves. It’s production.” Indeed! And production could be considerably ramped up if Big Pharma companies weren’t content to maintain existing factories at full capacity, rather than creating and repurposing new factories that will stand idle (and unprofitable) when the pandemic ends. It should be noted that no French company has managed to produce a vaccine as yet, meaning IP protection is a lesser concern from the perspective of French capitalism. This is unlike Germany, in which Pfizer’s partner BioNTech is based, and whose Chancellor Angela Merkel argued for preserving IP protections in order to ensure free market “innovation”, stating last Friday: “I believe that we need the creativity and innovative force of companies, and for me, this includes patent protection.” Merkel conveniently forgets that, since the beginning of the pandemic, state intervention has been a far more important influence over vaccine production than the ‘invisible hand’ of the market. The research that led to the COVID-19 technologies vaccines was overwhelmingly paid for out of the public purse. The AstraZeneca vaccine, for instance, was 97 percent publicly funded. Not to mention the billions spent by various states on purchasing doses. This has nothing to do with preserving ‘innovation’, and everything to do with protecting the private interests of German capitalism. Vaccine supremacy Despite misgivings from the likes of Germany, this latest move by the US might force the EU to change its tune. At a European Council summit on the weekend, President Charles Michel said: “[o]n the intellectual property, we don’t think in the short term that it’s the magic bullet but we are ready to engage on this topic as soon as a concrete proposal will be put on the table.” Still, Brussels is embittered at the US for refusing to offer any of its excess supply to help with shortages after the EU bungled its initial vaccine rollout. At the close of the summit, European Commission President Ursula von der Leyen again stated Europe was “open to discussion” on waiting IP, but mostly used the opportunity to strike back at the US: “The European Union is the pharmacy of the world and open to the world. Up to today in the European Union, 400 million doses of vaccines have been produced and 50 percent of them — 200 million doses — have been exported to 90 different countries in the world. So we invite others to do the same [this clearly means the US]. This is the best way right now in the short term to approach the bottlenecks and the lack of vaccines worldwide.” Belgian Prime Minister Alexander De Croo used even-sterner language: “As Europeans, we don’t need to be schooled. The U.S. hasn’t exported a single vaccine in the past six months. Europe is the one that’s been producing for itself and the rest of the world these past six months.” Now the European rollout is a bit more in hand (though still lagging behind the US and Britain, for example), the EU is trying to pursue vaccine diplomacy of its own to compete with China, Russia and the US in the race for vaccine supremacy. At the summit, Leyen announced plans to send more than 600,000 doses to countries in the Western Balkans, with further donations planned for countries in the Eastern Partnership group comprising Eastern Europe and the Caucasus. This notably includes Ukraine, which has already pleaded in vain with Washington for vaccines. While this is all going on, the EU is still waging a war with the British-based AstraZeneca company – taking them to court over delayed deliveries of vaccines. Once again, at a critical juncture in the fight against the pandemic, when global cooperation is most needed, the political leaders of bourgeoisie are embroiled in recriminations and shoring up their narrow national interests. No time for this madness! While the world leaders squabble, the nightmare continues for workers imprisoned by this pandemic. In her official statement to the WTO, Tai said: “negotiations [i.e. for the patent waiving] will take time”. But time is exactly what millions of workers that face the deadly virus today do not have. Because the WTO makes decisions by consensus, with any one of the 164 member states being able to block decisions, the end of November is considered a ‘realistic goal’ for presenting a draft agreement. This is seven months away! While tens of thousands of deaths are being recorded on a daily basis. When deadly new variants are devastating India and Latin America. It took less time to develop the first working vaccine than apparently, it will to agree a patent waiver on that vaccine! This is nothing short of insanity. Furthermore, the US statement to the WTO fell short of making explicit reference to the transferring of vaccine technology and know-how. If the technology underpinning vaccine production is not shared, even with a patent waiver, it will take months before manufacturers will be able to reverse-engineer a generic version, and months further to test it. The Big Pharma fat cats will not share their technology (which was publicly funded in the first place) voluntarily. They are forecasting sales for billions of dollars for 2021 and will do everything they can to push further back the development of generic versions. They can afford to drag things out. For them, time means billions in profits. The COVID-19 pandemic has shown capitalism for what it is. Rather than being a force for progress, private property and the nation state are the main obstacles preventing us from putting an end to the pandemic. Under a democratic, global plan of production we could put the mighty forces of industry and science at the service of society. All the necessary research, technology and expertise could be marshalled to fight this terrible virus. Vaccine production could be stepped up to reach the majority of the world population by the end of the year. It is capitalism alone that prevents this. We must fight the pandemic with class struggle! Expropriate the Big Pharma fat cats!

#### 2. Our critique independently outweighs the case - neoliberalism causes extinction and massive social inequalities – the affs single issue legalistic solution is the exact kind of politics neolib wants us to engage in so the root cause goes unquestioned. Farbod 15

( Faramarz Farbod , PhD Candidate @ Rutgers, Prof @ Moravian College, Monthly Review, http://mrzine.monthlyreview.org/2015/farbod020615.html, 6-2)

Global capitalism is the 800-pound gorilla. The twin ecological and economic crises, militarism, the rise of the surveillance state, and a dysfunctional political system can all be traced to its normal operations. We need a transformative politics from below that can challenge the fundamentals of capitalism instead of today's politics that is content to treat its symptoms. The problems we face are linked to each other and to the way a capitalist society operates. We must make an effort to understand its real character. The fundamental question of our time is whether we can go beyond a system that is ravaging the Earth and secure a future with dignity for life and respect for the planet. What has capitalism done to us lately? The best science tells us that this is a do-or-die moment. We are now in the midst of the 6th mass extinction in the planetary history with 150 to 200 species going extinct every day, a pace 1,000 times greater than the 'natural' extinction rate.1 The Earth has been warming rapidly since the 1970s with the 10 warmest years on record all occurring since 1998.2 The planet has already warmed by 0.85 degree Celsius since the industrial revolution 150 years ago. An increase of 2° Celsius is the limit of what the planet can take before major catastrophic consequences. Limiting global warming to 2°C requires reducing global emissions by 6% per year. However, global carbon emissions from fossil fuels increased by about 1.5 times between 1990 and 2008.3 Capitalism has also led to explosive social inequalities. The global economic landscape is littered with rising concentration of wealth, debt, distress, and immiseration caused by the austerity-pushing elites. Take the US. The richest 20 persons have as much wealth as the bottom 150 million.4 Since 1973, the hourly wages of workers have lagged behind worker productivity rates by more than 800%.5 It now takes the average family 47 years to make what a hedge fund manager makes in one hour.6 Just about a quarter of children under the age of 5 live in poverty.7 A majority of public school students are low-income.8 85% of workers feel stress on the job.9 Soon the only thing left of the American Dream will be a culture of hustling to survive. Take the global society. The world's billionaires control $7 trillion, a sum 77 times the debt owed by Greece to the European banks.10 The richest 80 possess more than the combined wealth of the bottom 50% of the global population (3.5 billion people).11 By 2016 the richest 1% will own a greater share of the global wealth than the rest of us combined.12 The top 200 global corporations wield twice the economic power of the bottom 80% of the global population.13 Instead of a global society capitalism is creating a global apartheid. What's the nature of the beast? Firstly, the "egotistical calculation" of commerce wins the day every time. Capital seeks maximum profitability as a matter of first priority. Evermore "accumulation of capital" is the system's bill of health; it is slowdowns or reversals that usher in crises and set off panic. Cancer-like hunger for endless growth is in the system's DNA and is what has set it on a tragic collision course with Nature, a finite category. Secondly, capitalism treats human labor as a cost. It therefore opposes labor capturing a fair share of the total economic value that it creates. Since labor stands for the majority and capital for a tiny minority, it follows that classism and class warfare are built into its DNA, which explains why the "middle class" is shrinking and its gains are never secure. Thirdly, private interests determine massive investments and make key decisions at the point of production guided by maximization of profits. That's why in the US the truck freight replaced the railroad freight, chemicals were used extensively in agriculture, public transport was gutted in favor of private cars, and big cars replaced small ones. What should political action aim for today? The political class has no good ideas about how to address the crises. One may even wonder whether it has a serious understanding of the system, or at least of ways to ameliorate its consequences. The range of solutions offered tends to be of a technical, legislative, or regulatory nature, promising at best temporary management of the deepening crises. The trajectory of the system, at any rate, precludes a return to its post-WWII regulatory phase. It's left to us as a society to think about what the real character of the system is, where we are going, and how we are going to deal with the trajectory of the system -- and act accordingly. The critical task ahead is to build a transformative politics capable of steering the system away from its destructive path. Given the system's DNA, such a politics from below must include efforts to challenge the system's fundamentals, namely, its private mode of decision-making about investments and about what and how to produce. Furthermore, it behooves us to heed the late environmentalist Barry Commoner's insistence on the efficacy of a strategy of prevention over a failed one of control or capture of pollutants. At a lecture in 1991, Commoner remarked: "Environmental pollution is an incurable disease; it can only be prevented"; and he proceeded to refer to "a law," namely: "if you don't put a pollutant in the environment it won't be there." What is nearly certain now is that without democratic control of wealth and social governance of the means of production, we will all be condemned to the labor of Sisyphus. Only we won't have to suffer for all eternity, as the degradation of life-enhancing natural and social systems will soon reach a point of no return**.**

#### 3. The alternative is to affirm the model of the Communist Party – only party organizing can provide effective accountability mechanisms to correct chauvinist tendencies, educate and mobilize marginalized communities, and connect local struggles to a movement for global liberation.

Elyson 18

Escalante, Philosophy @ UOregon, 18

[Alyson, M.A., is a Marxist-Leninist, Materialist Feminist and Anti-Imperialist activist. “PARTY ORGANIZING IN THE 21ST CENTURY” September 21st, 2018 <https://theforgenews.org/2018/09/21/party-organizing-in-the-21st-century/>] rVs

I would argue that within the base building movement, there is a move towards party organizing, but this trend has not always been explicitly theorized or forwarded within the movement. My goal in this essay is to argue that base building and dual power strategy can be best forwarded through party organizing, and that party organizing can allow this emerging movement to solidify into a powerful revolutionary socialist tendency in the United States. One of the crucial insights of the base building movement is that the current state of the left in the United States is one in which revolution is not currently possible. There exists very little popular support for socialist politics. A century of anticommunist propaganda has been extremely effective in convincing even the most oppressed and marginalized that communism has nothing to offer them. The base building emphasis on dual power responds directly to this insight. By building institutions which can meet people’s needs, we are able to concretely demonstrate that communists can offer the oppressed relief from the horrific conditions of capitalism. Base building strategy recognizes that actually doing the work to serve the people does infinitely more to create a socialist base of popular support than electing democratic socialist candidates or holding endless political education classes can ever hope to do. Dual power is about proving that we have something to offer the oppressed. The question, of course, remains: once we have built a base of popular support, what do we do next? If it turns out that establishing socialist institutions to meet people’s needs does in fact create sympathy towards the cause of communism, how can we mobilize that base? Put simply: in order to mobilize the base which base builders hope to create, we need to have already done the work of building a communist party. It is not enough to simply meet peoples needs. Rather, we must build the institutions of dual power in the name of communism. We must refuse covert front organizing and instead have a public face as a communist party. When we build tenants unions, serve the people programs, and other dual power projects, we must make it clear that we are organizing as communists, unified around a party, and are not content simply with establishing endless dual power organizations. We must be clear that our strategy is revolutionary and in order to make this clear we must adopt party organizing. By “party organizing” I mean an organizational strategy which adopts the party model. Such organizing focuses on building a party whose membership is formally unified around a party line determined by democratic centralist decision making. The party model creates internal methods for holding party members accountable, unifying party member action around democratically determined goals, and for educating party members in communist theory and praxis. A communist organization utilizing the party model works to build dual power institutions while simultaneously educating the communities they hope to serve. Organizations which adopt the party model focus on propagandizing around the need for revolutionary socialism. They function as the forefront of political organizing, empowering local communities to theorize their liberation through communist theory while organizing communities to literally fight for their liberation. A party is not simply a group of individuals doing work together, but is a formal organization unified in its fight against capitalism. Party organizing has much to offer the base building movement. By working in a unified party, base builders can ensure that local struggles are tied to and informed by a unified national and international strategy. While the most horrific manifestations of capitalism take on particular and unique form at the local level, we need to remember that our struggle is against a material base which functions not only at the national but at the international level. The formal structures provided by a democratic centralist party model allow individual locals to have a voice in open debate, but also allow for a unified strategy to emerge from democratic consensus. Furthermore, party organizing allows for local organizations and individual organizers to be held accountable for their actions. It allows criticism to function not as one independent group criticizing another independent group, but rather as comrades with a formal organizational unity working together to sharpen each others strategies and to help correct chauvinist ideas and actions. In the context of the socialist movement within the United States, such accountability is crucial. As a movement which operates within a settler colonial society, imperialist and colonial ideal frequently infect leftist organizing. Creating formal unity and party procedure for dealing with and correcting these ideas allows us to address these consistent problems within American socialist organizing. Having a formal party which unifies the various dual power projects being undertaken at the local level also allows for base builders to not simply meet peoples needs, but to pull them into the membership of the party as organizers themselves. The party model creates a means for sustained growth to occur by unifying organizers in a manner that allows for skills, strategies, and ideas to be shared with newer organizers. It also allows community members who have been served by dual power projects to take an active role in organizing by becoming party members and participating in the continued growth of base building strategy. It ensures that there are formal processes for educating communities in communist theory and praxis, and also enables them to act and organize in accordance with their own local conditions. We also must recognize that the current state of the base building movement precludes the possibility of such a national unified party in the present moment. Since base building strategy is being undertaken in a number of already established organizations, it is not likely that base builders would abandon these organizations in favor of founding a unified party. Additionally, it would not be strategic to immediately undertake such complete unification because it would mean abandoning the organizational contexts in which concrete gains are already being made and in which growth is currently occurring. What is important for base builders to focus on in the current moment is building dual power on a local level alongside building a national movement. This means aspiring towards the possibility of a unified party, while pursuing continued local growth. The movement within the Marxist Center network towards some form of unification is positive step in the right direction. The independent party emphasis within the Refoundation caucus should also be recognized as a positive approach. It is important for base builders to continue to explore the possibility of unification, and to maintain unification through a party model as a long term goal. In the meantime, individual base building organizations ought to adopt party models for their local organizing. Local organizations ought to be building dual power alongside recruitment into their organizations, education of community members in communist theory and praxis, and the establishment of armed and militant party cadres capable of defending dual power institutions from state terror. Dual power institutions must be unified openly and transparently around these organizations in order for them to operate as more than “red charities.” Serving the people means meeting their material needs while also educating and propagandizing. It means radicalizing, recruiting, and organizing. The party model remains the most useful method for achieving these ends. The use of the party model by local organizations allows base builders to gain popular support, and most importantly, to mobilize their base of popular support towards revolutionary ends, not simply towards the construction of a parallel economy which exists as an end in and of itself. It is my hope that we will see future unification of the various local base building organizations into a national party, but in the meantime we must push for party organizing at the local level. If local organizations adopt party organizing, it ought to become clear that a unified national party will have to be the long term goal of the base building movement. Many of the already existing organizations within the base building movement already operate according to these principles. I do not mean to suggest otherwise. Rather, my hope is to suggest that we ought to be explicit about the need for party organizing and emphasize the relationship between dual power and the party model. Doing so will make it clear that the base building movement is not pursuing a cooperative economy alongside capitalism, but is pursuing a revolutionary socialist strategy capable of fighting capitalism. The long term details of base building and dual power organizing will arise organically in response to the conditions the movement finds itself operating within. I hope that I have put forward a useful contribution to the discussion about base building organizing, and have demonstrated the need for party organizing in order to ensure that the base building tendency maintains a revolutionary orientation. The finer details of revolutionary strategy will be worked out over time and are not a good subject for public discussion. I strongly believe party organizing offers the best path for ensuring that such strategy will succeed. My goal here is not to dictate the only possible path forward but to open a conversation about how the base building movement will organize as it transitions from a loose network of individual organizations into a unified socialist tendency. These discussions and debates will be crucial to ensuring that this rapidly growing movement can succeed.

**4. The role of the ballot is to resist neoliberal ideology – filter negative arguments through an epistemological dismantling of neoliberalism.**

HAY & ROSAMUND, PhDs, 2002 (Colin and Ben, Journal of European Public Policy Volume 9, Issue 2, 2002 p. 3-5)

The implicit supposition which seems to underlie much of the sceptical or second-wave literature seeking to expose the ‘myth’ or ‘delusion’ of globalisation, is that a rigorous empirical exercise in demystification will be sufficient to reverse the tide of ill-informed public policy made in the name of globalisation. Sadly, this has not proved to be the case. For **however convinced we might be by the empirical armoury mustered against the hyperglobalisation thesis** by the sceptics, their **rigorous empiricism leads them to fail adequately to consider the way in which globalisation comes to inform public policy-making.** **It is here,** we suggest, that **the discourse of globalisation** — and the discursive construction of the imperatives it is seen to conjure along with attendant fatalism about the possibilities for meaningful political agency — **must enter the analysis**. For, as the most cursory reflection on the issue of structure and agency reveals, **it is the ideas actors hold about the context in which they find themselves** rather than the context itself **which informs the way in which they behave** (Hay 1999a, forthcoming a). **This is no less true of policy makers and governments**. **Whether** the **globalisation** thesis **is ‘true’** or not **may matter far less than whether it is deemed to be true** (or, quite possibly, just useful) **by those employing it**. Consequently, **if the aim** of the sceptics **is to discredit the political appeal to dubious economic imperatives associated with globalisation**, then they might **we**ll **benefit from asking** themselves **why and under what conditions** politicians and **public officials invoke** external **economic constraints** in the first place. It is to this task that we direct our attentions in this paper. Yet at the outset a certain word of caution is perhaps required. For, even if we accept the potential causal role that ideas about globalisation might play in the structuration of political and economic outcomes, we may be in danger of narrowing the discursive field of our attentions at the outset. The ideas policy makers use to legitimate and/or to rationalise their behaviour should not simply be seen as more or less accurate reflections of the context they perceive (based on more or less complete information). Nor should discourses be understood as necessarily and exclusively ‘strategic’ (i.e. as relating to situations in which an actor’s employment of a discourse correlates directly to particular material interests). **Discourse matters** in at least two respects. **The way** in which **actors behave is not merely a reflection** of the degree of accuracy and completeness **of the information they possess**; **it is also** a reflection of **their normative orientation** towards their environment and potential future scenarios. Thus the constraints and/or opportunities which globalisation is held to imply might be understood (or misunderstood) in very similar ways in different (national) contexts. Yet such understanding are likely to provoke divergent responses from political actors with different normative orientations and diverse institutional contexts. Put simply, **though actors may share a** common **understanding of** the process of **globalisation, they may respond** very **differently to its** perceived **challenges and threats** **depending on whether one regards the future it promises in a positive or negative light** – witness the still ongoing debate within the governing SPD in Germany between supporters of Schröder and Lafontaine (see Lafontaine 1998; Lafontaine and Müller 1998; Schröder 1998; and for a commentary Jeffery and Handl 1999), or that in France between Bourdieu, Forrester and anti-globalisation groups like ATTAC on the one hand and social liberals within the Parti Socialiste on the other (see Bourdieu 1998; Boudieu and Wacquant 1999; Forrester 1999; and for a commentary Bouvet and Michel 1999; Meunier 2000). Within the European Commission, there is evidence to suggest that common understandings of globalisation can be quite consistent with distinct conceptions of the capacity to exercise meaningful agency as actors take up quite different ‘subject positions’ in relation to globalisation (Rosamond, 1999; 2000b). **It is important**, then, at the outset **that we consider the potential causal role of ideas about globalisation in the structuration of political and economic outcomes**.3 Our central argument is, we think, likely to prove controversial. It is simply stated, though its implications are more complex. Essentially, we suggest, **policy makers acting on the basis of assumptions consistent with the hyperglobalisation thesis may well serve**, in so doing, **to bring about outcomes consistent with that thesis, irrespective of its veracity and,** indeed, irrespective of its perceived veracity**.** This provocative suggestion with, if warranted, important implications, clearly requires some justification (see also Hay 1999b; Rosamond 1999, 2000b, 2000c). **Globalisation has become** a key referent of contemporary political discourse and, increasingly, **a lens through which policy-makers view the context in which they find themselves.** **If** we can assume that political actors have no more privileged vantage point from which to understand their environment than anyone else and — as most commentators would surely concede — that **one of the principal discourses through which that environment now comes to be understood is that of globalisation, then the content of such ideas is likely to affect significantly political dynamics.**

## 3

#### Text: The People’s Republic of China should offer Chinese developed vaccines and medical technology related to COVID-19 to the world for free

#### 1. The CP massively ramps up Chinese “vaccine diplomacy” which solves the case

Juecheng and Yuwei 8-13-21

(Zhao and Hu, https://www.globaltimes.cn/page/202108/1231387.shtml)

One of China’s most valued contributions to the global fair accessibility to COVID-19 vaccines is to enable more developing countries to hone their ability to produce vaccines by themselves, Zha Daojiong, professor of International Political Economy from Peking University, who closely studies the global vaccine equitable allocation framework, told the Global Times in a recent exclusive interview. Sharing his insights on widely discussed “vaccine nationalism,” “wavering vaccine intellectual property,” and “COVAX operation challenges,” Zha believes that China is advocating negotiations among countries on equitable global distribution of vaccines from a humanitarian, and global perspective. China has vowed to make efforts to provide the world with 2 billion doses of COVID-19 vaccines this year and donate $100 million to COVAX to promote global vaccine provision. This commitment comes amid the rampaging Delta variant, which is bringing more challenges for developing countries to access vaccines and combat the pandemic while the West continues to drag its heels in fulfilling its promises. The promise was made at the first meeting of a forum on international cooperation on COVID-19 vaccines held on August 5. Zha suggested that the forum, alongside the Initiative for Belt and Road Partnership on COVID-19 Vaccine Cooperation, reflect China’s efforts to support long-term cooperation in the vaccine industry globally. However, some Western media have labeled China and Russia as the pioneers of the global "vaccine diplomacy" campaign. The choice of vaccines by countries has become the epitome of global geopolitics.   Foreign comments on China using "vaccine diplomacy" in a narrow geopolitical sense reflect the real competition among COVID-19 vaccine providers, Zha told the Global Times. Due to China’s mature vaccine technologies, longer shelf life and lower requirement for storage and transportation, Chinese made vaccines are a more preferable choice for many developing countries with relatively weak vaccination infrastructure . This has been reflected in the approval of Chinese vaccines in more than 100 countries. But the phenomenon of “vaccine nationalism” was never absent in the decision by governments to choose vaccines, Zha suggested. “For example, some countries and regions would include geopolitical factors in choosing vaccines. These countries would reject certain vaccines. Moreover, some media outlets refuse to accept the fact that the professional assessment of vaccine efficacy is also a scientific process. Instead, they made comments on potential vaccines based on their geopolitical interests. This is also a kind of “vaccine nationalism”. Voices blaming “vaccine nationalism” have long been present in developed countries. For instance, Zha recalled how, during the H1N1 pandemic of 2009 which affected more than 200 countries and regions for more than a year, certain developed countries bought out entire stocks of vaccines against H1N1 once they were developed. Though some of those countries had promised to donate vaccines to others after they met their vaccination needs, the virus had long disappeared before their donations were made. Therefore, many in other nations lost the opportunity of a timely vaccination. Providing assistance from one country to another in the field of infectious or non-infectious diseases is often referred to as "health diplomacy." Some international public health research literature support "health diplomacy" because cooperation in this field is conducive to the improvement of political, economic and diplomatic relations, Zha said. China has taken important steps to close the global vaccine gap, including the acceleration of large-scale production, boosting fair distribution, and licensing local production in more countries.

#### 2. Successful vaccine diplomacy is key to overall Chinese Soft Power

Huang, PhD, 3-11-21

(YANZHONG HUANG is Senior Fellow for Global Health at the Council on Foreign Relations, a Professor at Seton Hall University’s School of Diplomacy and International Relations, and Director of the school’s Center for Global Health Studies. https://www.foreignaffairs.com/articles/china/2021-03-11/vaccine-diplomacy-paying-china )

Vaccines have had a place in diplomacy since the Cold War era. The country that can manufacture and distribute lifesaving injections to others less fortunate sees a return on its investment in the form of soft power: prestige, goodwill, perhaps a degree of indebtedness, even awe. Today the country moving fastest toward consolidating these gains may be China, under President Xi Jinping, who proclaimed last May that Chinese-made vaccines against COVID-19 would become a “global public good.” Since that time, top officials have promised many developing countries priority access to Chinese vaccines, and the Chinese Foreign Ministry has announced that the country is providing free vaccines to 69 countries and commercially exporting them to 28 more. China’s competitors worry that where Beijing’s inoculations go, its influence will follow. But the field of COVID-19 vaccination is still a largely uncharted one and scattered with barriers, whether logistical, scientific, psychological, or geopolitical. China’s path through this labyrinth is neither obvious nor assured. The country faces stiffening competition from Russia and India. Now the United States, too, has entered the global stakes for equitable distribution of safe and effective vaccines. China has yet to prove that it can fulfill the role it has taken on or win the trust of those it has offered to aid. CHINA'S STAKE The Chinese government dislikes the term “vaccine diplomacy.” The implication that China would distribute vaccine doses in order to broaden its global political influence is a “sinister” one, according to the official Xinhua News Agency. Rather, the Chinese government contends that “in promoting cooperation in combating the pandemic, China does not seek any geopolitical goals or have any economic interest considerations, and it has never attached any political strings.” Xi has further stressed that by distributing necessary goods in a crisis, China is merely acting as a responsible great power should. In this regard, China may seek to succeed with vaccines where it failed with masks: last spring, quality-control issues and clumsy propaganda tarnished the country’s efforts to supply medical products to the developed world. Now China is looking to showcase its global health leadership to lower- and middle-income countries, where it is distributing vaccines. But Beijing surely has additional foreign policy objectives in mind. China began its vaccine development projects early last spring, and state media made quite clear that through them, China hoped to demonstrate its technological prowess and the superiority of its authoritarian model of governance. “We are not lagging behind the United States as far as the technology is concerned,” a Chinese virologist told the state-backed Global Times. Another scientist highlighted China’s “system advantages”: “The United States is no match for China in terms of concentrating power to accomplish big things.” Indeed, unlike in the United States, vaccine development in China was a highly state-driven process. The Chinese government simultaneously pushed several technological approaches, including inactivated vaccines, mRNA vaccines, and adenovirus vector vaccines. It mobilized at least 22 institutes and firms to work on 17 vaccine development projects. And until last summer, China was leading the global race in vaccine development. It developed a vaccine (Ad5-nCoV) as early as February 2020, started Phase 1 clinical trials on March 16, and published results of the trials in late May. General Chen Wei, the face of China’s vaccine development operation, celebrated such achievements as “an embodiment of our country’s S&T progress, an embodiment of China’s great-power image and responsibility, and, even more, a contribution to humankind.” Behind such lofty goals lie commercial objectives, too. Health-related development assistance has long offered Chinese pharmaceutical companies a low-cost means of expanding their market share in the developing world. In March 2020, President Xi explicitly linked the shipment of medical supplies overseas to the “Health Silk Road,” now an important component of the Belt and Road Initiative. Xiaofeng Liang, a former deputy director of the Chinese Center for Disease Control and Prevention, has publicly called for prioritizing BRI countries for access to Chinese vaccines. But the opportunity hardly ends there. Prior to the COVID-19 pandemic, few Chinese pharmaceutical companies had received World Health Organization prequalification to supply medical products to international organizations and donor funds. In 2019, China’s share in the value of UN-procured medical products was only 1.9 percent, compared with 21.9 percent for India. Chinese media lamented that of the 155 WHO-prequalified vaccines, only four were from China, compared with 44 from India. Indeed, Indian pharmaceutical firms produced more than 60 percent of the vaccines sold worldwide. The huge global demand for COVID-19 vaccines and “vaccine nationalism” in wealthy nations have created a great opportunity for China to break into a market that Indian and Western pharmaceutical firms have long dominated. If the vaccine were priced at $10 per dose with a 40 percent net profit margin, even a 15 percent share of the vaccine market in lower- and middle-income countries would generate total sales of $10.8 billion and a profit of $4.32 billion for the Chinese economy. In reality, Chinese vaccines are often priced higher than $10.

**3. Chinese leadership solves extinction.**

Shen **Yamei 18**, Deputy Director and Associate Research Fellow of Department for American Studies, China Institute of International Studies, 1-9-2018, "Probing into the “Chinese Solution” for the Transformation of Global Governance," CAIFC, http://www.caifc.org.cn/en/content.aspx?id=4491

As the world is in a period of great development, transformation and adjustment, the international power comparison is undergoing profound changes, global governance is reshuffling and traditional governance concepts and models are confronted with challenges. The international community is expecting China to play a bigger role in global governance, which has given birth to the Chinese solution. A. To Lead the Transformation of the Global Governance System. **The “shortcomings” of the existing global governance system are prominent, which can hardly ensure global development. First, the traditional dominant forces are seriously imbalanced**. The US and Europe that used to dominate the global governance system have been beset with structural problems, with their economic development stalling, social contradictions intensifying, populism and secessionism rising, and states trapped in internal strife and differentiation. These countries have not fully reformed and adjusted themselves well, but rather pointed their fingers at globalization and resorted to retreat for self-insurance or were busy with their own affairs without any wish or ability to participate in global governance, which has encouraged the growth of “anti-globalization” trend into an interference factor to global governance. Second, the global governance mechanism is relatively lagging behind. Over the years of development, the strength of emerging economies has increased dramatically, which has substantially upset the international power structure, as the developing countries as a whole have made 80 percent of the contributions to global economic growth. These countries have expressed their appeal for new governance and begun policy coordination among themselves, which has initiated the transition of global governance form “Western governance” to “East-West joint governance”, but **the traditional governance mechanisms such as the World Bank, IMF and G7 failed to reflect the demand of the new pattern, in addition to their lack of representation and inclusiveness.** Third, the global governance rules are developing in a fragmented way, with governance deficits existing in some key areas. With the diversification and in-depth integration of international interests, the domain of global governance has continued to expand, with actors multiplying by folds and action intentions becoming complicated. As relevant efforts are usually temporary and limited to specific partners or issues, global governance driven by requests of “diversified governance” lacks systematic and comprehensive solutions. Since the beginning of this year, there have been risks of running into an acephalous state **in such key areas as global economic governance and climate change**. **Such emerging issues as nuclear security and international terrorism have suffered injustice because of power politics**. **The governance areas in deficit, such as cyber security, polar region and oceans, have “reversely forced” certain countries and organizations to respond hastily**. All of these have made the global governance system trapped in a dilemma and call urgently for a clear direction of advancement. B. To Innovate and Perfect the International Order. Currently, whether the developing countries or the Western countries of Europe and the US are greatly discontent with the existing international order as well as their appeals and motivation for changing the order are unprecedentedly strong. The US is the major creator and beneficiary of the existing hegemonic order, but it is now doubtful that it has gained much less than lost from the existing order, faced with the difficulties of global economic transformation and obsessed with economic despair and political dejection. Although the developing countries as represented by China acknowledge the positive role played by the post-war international order in safeguarding peace, boosting prosperity and promoting globalization, they criticize the existing order for lack of inclusiveness in politics and equality in economy, as well as double standard in security, believing it has failed to reflect the multi-polarization trend of the world and is an exclusive “circle club”. Therefore, there is much room for improvement. For China, to lead the transformation of the global governance system and international order not only supports the efforts of the developing countries to uphold multilateralism rather than unilateralism, advocate the rule of law rather than the law of the jungle and practice democracy rather than power politics in international relations, but also is an important subject concerning whether China could gain the discourse power and development space corresponding to its own strength and interests in the process of innovating and perfecting the framework of international order. C. To Promote Integration of the Eastern and Western Civilizations. Dialog among civilizations, which is the popular foundation for any country’s diplomatic proposals, runs like a trickle moistening things silently. Nevertheless, in the existing international system guided by the “Western-Centrism”, the Western civilization has always had the self-righteous superiority, conflicting with the interests and mentality of other countries and having failed to find the path to co-existing peacefully and harmoniously with other civilizations. **So to speak, many problems of today, including the growing gap in economic development between the developed and developing countries against the background of globalization, the Middle East trapped in chaos and disorder, the failure of Russia and Turkey to “integrate into the West”, etc., can be directly attributed to lack of exchanges, communication and integration among civilizations.** Since the 18th National Congress of CPC, Xi Jinping has raised the concept of “Chinese Dream” that reflects both Chinese values and China’s pursuit, re-introducing to the world the idea of “all living creatures grow together without harming one another and ways run parallel without interfering with one another”, which is the highest ideal in Chinese traditional culture, and striving to shape China into a force that counter-balance the Western civilization. He has also made solemn commitment that “we respect the diversity of civilizations …… cannot be puffed up with pride and depreciate other civilizations and nations”; “facing the people deeply trapped in misery and wars, we should have not only compassion and sympathy, but also responsibility and action …… do whatever we can to extend assistance to those people caught in predicament”, etc. China will rebalance the international pattern from a more inclusive civilization perspective and with more far-sighted strategic mindset, or at least correct the bisected or predominated world order so as to promote the parallel development of the Eastern and Western civilizations through mutual learning, integration and encouragement. D. To Pass on China’s Confidence. Only a short while ago, some Western countries had called for “China’s responsibility” and made it an inhibition to “regulate” China’s development orientation. Today, China has become a source of stability in an international situation full of uncertainties. Over the past 5 years, China has made outstanding contributions to the recovery of world economy under relatively great pressure of its own economic downturn. Encouraged by the “four confidences”, the whole of the Chinese society has burst out innovation vitality and produced innovation achievements, making people have more sense of gain and more optimistic about the national development prospect. It is the heroism of the ordinary Chinese to overcome difficulties and realize the ideal destiny that best explains China’s confidence. When this confidence is passed on in the field of diplomacy, it is expressed as: first, China’s posture is seen as more forging ahead and courageous to undertake responsibilities ---- proactively shaping the international agendas rather than passively accepting them; having clear-cut attitudes on international disputes rather than being equivocal; and extending international cooperation to comprehensive and dimensional development rather than based on the theory of “economy only”. In sum, China will actively seek understanding and support from other countries rather than imposing its will on others with clear-cut Chinese characteristics, Chinese style and Chinese manner. Second, China’s discourse is featured as a combination of inflexibility and yielding as well as magnanimous ---- combining the internationally recognized diplomatic principles with the excellent Chinese cultural traditions through digesting the Chinese and foreign humanistic classics assisted with philosophical speculations to make “China Brand, Chinese Voice and China’s Image get more and more recognized”. Third, the Chinese solution is more practical and intimate to people as well as emphasizes inclusive cooperation, as China is full of confidence to break the monopoly of the Western model on global development, “offering mankind a Chinese solution to explore a better social system”, and “providing a brand new option for the nations and peoples who are hoping both to speed up development and maintain independence”. II.Path Searching of the “Chinese Solution” for Global Governance Over the past years’ efforts, China has the ability to transform itself from “grasping the opportunity” for development to “creating opportunity” and “sharing opportunity” for common development, hoping to pass on the longing of the Chinese people for a better life to the people of other countries and promoting the development of the global governance system toward a more just and rational end. It has become the major power’s conscious commitment of China to lead the transformation of the global governance system in a profound way. A. To Construct the Theoretical System for Global Governance. The theoretical system of global governance has been the focus of the party central committee’s diplomatic theory innovation since the 18th National Congress of CPC as well as an important component of the theory of socialism with Chinese characteristics for a new era, which is not only the sublimation of China’s interaction with the world from “absorbing and learning” to “cooperation and mutual learning”, but also the cause why so many developing countries have turned from “learning from the West” to “exploring for treasures in the East”. In the past 5 years, the party central committee, based on precise interpretation of the world pattern today and serious reflection on the future development of mankind, has made a sincere call to the world for promoting the development of global governance system toward a more just and rational end, and proposed a series of new concepts and new strategies including engaging in major power diplomacy with Chinese characteristics, creating the human community with common destiny, promoting the construction of new international relationship rooted in the principle of cooperation and win-win, enriching the strategic thinking of peaceful development, sticking to the correct benefit view, formulating the partnership network the world over, advancing the global economic governance in a way of mutual consultation, joint construction and co-sharing, advocating the joint, comprehensive, cooperative and sustainable security concept, and launching the grand “Belt and Road” initiative. The Chinese solution composed of these contents, not only fundamentally different from the old roads of industrial revolution and colonial expansion in history, but also different from the market-driven neo-liberalism model currently advocated by Western countries and international organizations, stands at the height of the world and even mankind, seeking for global common development and having widened the road for the developing countries to modernization, which is widely welcomed by the international community. B. To Supplement and Perfect the Global Governance System. Currently, the international political practice in global governance is mostly problem-driven without creating a set of relatively independent, centralized and integral power structures, resulting in the existing global governance systemcharacterized as both extensive and unbalanced. China has been engaged in reform and innovation, while maintaining and constructing the existing systems, producing some thinking and method with Chinese characteristics. First, China sees the UN as a mirror that reflects the status quo of global governance, which should act as the leader of global governance, and actively safeguards the global governance system with the UN at the core. Second, China is actively promoting the transforming process of such recently emerged international mechanisms as G20, BRICS and SCO, perfecting them through practice, and boosting Asia-Pacific regional cooperation and the development of economic globalization. China is also promoting the construction of regional security mechanism through the Six-Party Talks on Korean Peninsula nuclear issue, Boao Forum for Asia, CICA and multilateral security dialog mechanisms led by ASEAN so as to lay the foundation for the future regional security framework. Third, China has initiated the establishment of AIIB and the New Development Bank of BRICS, creating a precedent for developing countries to set up multilateral financial institutions. The core of the new relationship between China and them lies in “boosting rather than controlling” and “public rather than private”, which is much different from the management and operation model of the World Bank, manifesting the increasing global governance ability of China and the developing countries as well as exerting pressure on the international economic and financial institution to speed up reforms. **Thus, in leading the transformation of the global governance system, China has not overthrown the existing systems and started all over again, but been engaged in innovating and perfecting; China has proactively undertaken international responsibilities, but has to do everything in its power and act according to its ability.** C. To Reform the Global Governance Rules. Many of the problems facing global governance today are deeply rooted in such a cause that the dominant power of the existing governance system has taken it as the tool to realize its own national interests first and a platform to pursue its political goals. Since the beginning of this year, the US has for several times requested the World Bank, IMF and G20 to make efforts to mitigate the so-called global imbalance, abandoned its commitment to support trade openness, cut down investment projects to the middle-income countries, and deleted commitment to support the efforts to deal with climate change financially, which has made the international systems accessories of the US domestic economic agendas, dealing a heavy blow to the global governance system. On the contrary, the interests and agendas of China, as a major power of the world, are open to the whole world, and China in the future “will provide the world with broader market, more sufficient capital, more abundant goods and more precious opportunities for cooperation”, while having the ability to make the world listen to its voice more attentively. With regard to the subject of global governance, China has advocated that what global governance system is better cannot be decided upon by any single country, as the destiny of the world should be in the hands of the people of all countries. In principle, all the parties should stick to the principle of mutual consultation, joint construction and co-sharing, resolve disputes through dialog and differences through consultation. Regarding the critical areas, opening to the outer world does not mean building one’s own backyard, but building the spring garden for co-sharing; the “Belt and Road” initiative is not China’s solo, but a chorus participated in by all countries concerned. **China has also proposed international public security views on nuclear security, maritime cooperation and cyber space order, calling for efforts to make the global village into a “grand stage for seeking common development” rather than a “wrestling arena”; we cannot “set up a stage here, while pulling away a prop there”, but “complement each other to put on a grand show”**. From the orientation of reforms, efforts should be made to better safeguard and expand the legitimate interests of the developing countries and increase the influence of the emerging economies on global governance. Over the past 5 years, China has attached importance to full court diplomacy, gradually coming to the center stage of international politics and proactively establishing principles for global governance. By hosting such important events as IAELM, CICA Summit, G20 Summit, the Belt and Road International Cooperation Forum and BRICS Summit, China has used theseplatforms to elaborate the Asia-Pacific Dream for the first time to the world, expressing China’s views on Asian security and global economic governance, discussing with the countries concerned with the Belt and Road about the synergy of their future development strategies and setting off the “BRICS plus” capacity expansion mechanism, in which China not only contributes its solution and shows its style, but also participates in the shaping of international principles through practice. On promoting the resolution of hot international issues, China abides by the norms governing international relations based on the purposes and principles of the UN Charter, and insists on justice, playing a constructive role as a responsible major power in actively promoting the political accommodation in Afghanistan, mediating the Djibouti-Eritrea dispute, promoting peace talks in the Middle East, devoting itself to the peaceful resolution of the South China Sea dispute through negotiations. In addition, China’s responsibility and quick response to international crises have gained widespread praises, as seen in such cases as assisting Africa in its fight against the Ebola epidemic, sending emergency fresh water to the capital of Maldives and buying rice from Cambodia to help relieve its financial squeeze, which has shown the simple feelings of the Chinese people to share the same breath and fate with the people of other countries. D. To Support the Increase of the Developing Countries’ Voice. The developing countries, especially the emerging powers, are not only the important participants of the globalization process, but also the important direction to which the international power system is transferring. With the accelerating shift of global economic center to emerging markets and developing economies, the will and ability of the developing countries to participate in global governance have been correspondingly strengthened. As the biggest developing country and fast growing major power, China has the same appeal and proposal for governance as other developing countries and already began policy coordination with them, as China should comply with historical tide and continue to support the increase of the developing countries’ voice in the global governance system. To this end, China has pursued the policy of “dialog but not confrontation, partnership but not alliance”, attaching importance to the construction of new type of major power relationship and global partnership network, while making a series proposals in the practice of global governance that could represent the legitimate interests of the developing countries and be conducive to safeguarding global justice, including supporting an open, inclusive, universal, balanced and win-win economic globalization; promoting the reforms on share and voting mechanism of IMF to increase the voting rights and representation of the emerging market economies; financing the infrastructure construction and industrial upgrading of other developing countries through various bilateral or regional funds; and helping other developing countries to respond to such challenges as famine, refugees, climate change and public hygiene by debt forgiveness and assistance.

# 2NR

### OV- Pharma

#### Pharma profits are currently up from COVID vaccines, and this is something we should try our best to preserve- waiving IP protection threatens this and prefer our evidence because we provide statistical analysis- strong IP protection spurs innovation whereas a waiver does not, companies aren’t incentivized to create new things if they don’t get the rights to said things- lack of pharmaceutical innovation risks bioterror and pandemics which guarantees extinction.

**AT Mergers Thump**

**Pharma M&As improve innovation. Concerns regarding consolidation are based on an outdated understanding of the pharma ecosystem.**

**Shepherd 17** (Joanna Shepherd, PhD Law @ Emory University. "The Relationship Between Consolidation and Innovation in the Drug Industry," Columbia Law School Blog, 4-24-2017, https://clsbluesky.law.columbia.edu/2017/04/24/the-relationship-between-consolidation-and-innovation-in-the-drug-industry/)

The prescription drug industry has undergone a significant transformation in recent decades. The intensifying competition from generic drugs, the expanding power of entities that pay for drugs and negotiate drug prices, the increasing costs of drug development and gaining approval from the Food and Drug Administration, and the growing risks of commercial failure have strained the finances of many traditional drug companies. **Many companies have responded by consolidating to either reduce costs or create new sources of revenue**. As a result, the number of mergers and acquisitions (M&A) in the pharmaceutical industry recently hit an all-time high. As pharmaceutical M&A has soared, so too has concern over the impacts of consolidation on the drug industry. While most of the scrutiny has focused on the potential harm to existing competition, researchers and regulatory agencies have also raised less-traditional concerns about harms to future innovation in the newly-merged firms. These concerns are premised on the idea that merging competitors into one firm will reduce incentives to develop new drugs. Merger analyses in innovative industries other than the drug industry are also increasingly incorporating innovation effects. In fact, three of the largest proposed mergers today— Monsanto/Bayer, Dow/Dupont, and ChinaChem/Syngenta—have faced scrutiny in both the U.S. and Europe over concerns that the mergers will slow innovation in agricultural biotechnology. However, as I explain in my recent article, “Consolidation and Innovation in the Pharmaceutical Industry: The Role of Mergers and Acquisitions in the Current Innovation Ecosystem,” **concerns about consolidation’s impact on drug innovation are largely based on an outdated understanding of the innovation ecosystem in the pharmaceutical industry.** Today, most drug innovation originates not in traditional pharmaceutical companies but in biotech companies and smaller firms, where a culture of nimble decision-making and risk-taking facilitates discovery and innovation. In fact, about two-thirds of New Molecular Entities approved by the FDA originate in biotech and small pharmaceutical companies, and these companies account for almost 70 percent of the current global pipeline of drugs under development. To complete the development process and commercialize their drugs, biotech companies regularly collaborate with large pharmaceutical companies that push drugs through the grueling late-stage clinical trials and regulatory hurdles of the FDA, organize their manufacturing and distribution capabilities to bring the drugs to market, and mobilize their vast sales force to quickly achieve peak sales. In this current ecosystem, each biotech and pharmaceutical firm can specialize in what it does best, bringing expertise and efficiencies to the innovation process. This specialization has dramatically changed the share of internally-developed versus externally-developed drugs in the pharmaceutical industry. Whereas in the 1970s and early 1980s, almost all drug discovery and early stage development took place inside traditional drug companies, today, the companies increasingly shift resources away from internal R&D expenditures and projects and towards external sources of innovation. Externally-sourced drugs now account for an incredible 74 percent of new drugs registered with the FDA for sale in the U.S. Internal R&D is no longer the primary source of drug innovation in large pharmaceutical companies. **As a result, antitrust analyses that focus on pharmaceutical mergers’ impacts on internal R&D and innovation largely miss the point.** In the current innovation ecosystem, where little drug innovation originates internally, a merger’s impact on internal R&D expenditures or development projects is often immaterial to aggregate drug innovation. Certainly, concerns about harm to innovation could be relevant in specific mergers or acquisitions if the consolidating firms are the primary innovators in an area, the firms innovate internally, and there are limited sources of external innovation. However, such scenarios are increasingly rare in the drug industry. Instead, proper analyses of the impacts of consolidation on innovation should focus on whether consolidation enables firms to better support aggregate drug innovation in the current innovation ecosystem. In many consolidated firms, increases in efficiency and streamlining of operations free up money and resources to acquire external innovation. The resulting boost in demand for externally-sourced innovation increases the prices of external assets, which, in turn, encourages more early-stage innovation in small firms and biotech companies. Aggregate drug innovation increases in the process. Drug industry analysts expect the already heightened pace of M&A activity to pick up under the Trump administration, as stock prices rise and proposed tax reforms encourage deal-making. Policymakers must understand the role of consolidation in the current innovation ecosystem and evaluate mergers for their likely impacts on aggregate drug innovation.

**Mergers significantly improve productivity and innovation. Previous studies fail to employ rigorous or systematic data analysis.**

**Ringel and Choy 17 (**Michael S. Ringel and Michael K. Choy July 24, 2017, partners @ Boston Consulting Group. "A new wave of pharma mergers could put innovative drugs in the pipeline," STAT, 7-24-2017, https://www.statnews.com/2017/07/24/mergers-pharma-drug-development/)

**A new wave of pharmaceutical industry mergers may be on the horizon**, driven in part by the $1.3 trillion in overseas cash that U.S. corporations currently hold. If policymakers provide a tax holiday on repatriation of these funds, some experts say that U.S. pharmaceutical companies would be flush with cash and could likely spend a meaningful portion of this windfall on mergers. While big mergers could have many impacts — on employment at home and abroad, competition, and drug prices, to name a few — one of the most important would be the effect on research and development productivity and innovation. Analysts have tackled this topic before. Their work has been of mixed quality and, perhaps not surprisingly, has yielded mixed results. Pundits at the Institute for Competition Economics in Dusseldorf, Germany, for example, claimed last year in a Harvard Business Review article that previous drug company mergers had “substantially” reduced R&D and innovation, not only at the merging firms but at the merging firms’ competitors as well. Another team, this one from Duke University, the University of Toronto, and Baruch College/CUNY, reached a different conclusion with its data-driven approach. The team’s review of hundreds of mergers and acquisitions from 1985 to 2009, published in Loyola University Chicago Law Journal, indicated that the correlation between merger and acquisition activity and FDA approvals of new drugs is “moderately positive,” both at an industry level and individual firm level. Who’s right? Are those in need of new lifesaving drugs harmed by consolidation in the pharmaceutical industry, or are they helped? Related Story: Will pharma use a tax break to create new jobs? That’s not what happened last time We believe that **one of the main problems with much of the previous research in this area has been an over-reliance on anecdotal reporting rather than employing systematic data analysis**. Even when such analysis has been done, researchers have sometimes focused on research and development spending or patent activity as benchmarks of success, as if these metrics are indicators of — or even synonymous with — actual product innovation. But they aren’t necessarily the same. Spending is just an input, measured in dollars or some other currency. The same is true with patents. There is a long distance between the laboratory where new compounds are discovered and the corner drugstore where medicines are purchased. We sought to address this uncertainty by focusing on research and development productivity: the amount of innovation created as measured by the value of new FDA-approved compounds reaching the pharmacy, relative to input. After all, what matters to patients is the creation of quality medicines, not how much a company spends on research and development or the number of patent applications it files. To determine whether mega-mergers benefit patients, we looked at what happened to research and development productivity in all of the major mergers going back to 2001, including the last big wave in 2009 that brought together Merck & Co. and Schering-Plough, Pfizer and Wyeth, and Roche and Genentech. As expected, the results varied from year to year and company to company. But **our report in Drug Discovery Today showed that mergers generally appeared to drive productivity up — and did so significantly.** Why might this be so? While mergers undoubtedly bring disruption to research and development, they also can be catalysts for addressing the fatal flaw of most research and development enterprises: the high cost of failure. More than 90 percent of pharmaceutical industry spending on research and development goes into projects that never reach the market. Any intervention that helps reduce this waste can be a real boon to productive. There are really only two ways to fix the industry’s cost-of-failure problem: 1) start with better science, so you have fewer failures; and 2) employ better decision-making about when to stop projects so you can reallocate that capital to more-promising opportunities. **Mergers can help with both of these** dimensions. They bring the best combined science of the merged organizations to bear on the difficult questions of which pathways, modalities, and molecules to pursue. Mergers also trigger reviews that drive the leadership of the new company to take a fresh look at research and development. These reviews can offer the leadership an opportunity to soberly and objectively reassess its scientific hypotheses in each disease area and reevaluate the combined research and development portfolio, eliminating those projects least likely to produce advances in treatment. This spring cleaning can have a cathartic effect. The combination of the two factors — fresh science and a fresh look at the portfolio — can create a renewed research and development enterprise better able to bring new medicines to patients. Our analysis doesn’t suggest that all mergers are good. Even from the perspective of research and development productivity, some mergers in our study appeared to have depressed the flow of new medicines to patients by slowing down or stopping promising projects. And there are considerations beyond the scope of our analysis, such as jobs or drug prices, that may be equally valid inputs to views about mergers and acquisitions. **Overall, however, the evidence indicates that large mergers increase, not decrease, the productivity of pharmaceutical research and development** — good news for those in need of new therapies.

### AT: Aff is Anti-Capitalist

#### The aff case implicitly supports capitalism by trying to solve its effects, such as rampant corporate greed, instead of addressing the root problem—the private ownership of capital.

#### We should refuse the demand for pragmatic alternatives- radical break in thinking is precondition to change

**Zwick, PhD, 13**

(Detlev, Associate Professor of Marketing *The myth of metaphysical enclosure: A second response to Adam Arvidsson* <http://www.ephemerajournal.org/contribution/myth-metaphysical-enclosure-second-response-adam-arvidsson>) JJN from File

The second charge against my initial response was that all that criticizing is all well and good but, unless it is combined with a solution, such criticism is not constructive. A reactionary response to criticism that aims at foreclosing critical discourse, such a demand for constructiveness and practical solutions, should be rejected unconditionally. First, on moral grounds, why should it be acceptable for someone who posits as a ‘solution’ a utopian fantasy (hence no solution at all) to demand from his or her detractors a solution? Second, we should reject the notion that criticism should always be constructive on theoretical grounds. Constructivist criticism is a kind of criticism that accepts the coordinates of the real within which the criticized object resides. If criticism rejects the assumptions on which the critiqued rests, or put differently, if criticism rejects as unacceptable the entire symbolic universe that make possible the criticized object, then it cannot be called constructive. Often, then, constructive criticism becomes meaningless criticism. For example, how would one provide constructive criticism of Hitler’s ideological and political project? Such a task would make little sense because it would cast a priori Hitler’s Third Reich as a reasonable entity (see Horkheimer, 2004). Similarly, when Arvidsson calls for us to start behaving like reasonable and constructive people, what he means is that we should accept the coordinates of his argument – for example, that neoliberal capitalism has to be accepted as a reality and by doing so we can move beyond it – as a reasonable entity. Trying to change these coordinates becomes unreasonable and unconstructive. Here again we should remember Žižek’s advice to the Wall Street occupiers not to speak to all those agents of reason, those pragmatists, from Clinton to Obama to Goldman Sachs. At such moments of resistance and defiance, silence becomes the most radical act against pragmatic politics, the kind of politics that wants to resolve the problem step by step in a realistic way, rather than addressing it at its roots (see Žižek, 2008). Because what would Arvidsson’s response be to anything outside the existing coordinates he sees structuring the domain of social and economic relations? Perhaps, then, this is not the time to articulate solutions when we are still struggling to ask the right questions. This sentiment is expressed perfectly by a joke Žižek told at Occupy Wall Street[2], In an old joke from the defunct German Democratic Republic, a German worker gets a job in Siberia; aware of how all mail will be read by censors, he tells his friends: ‘Let’s establish a code: if a letter you will get from me is written in ordinary blue ink, it is true; if it is written in red ink, it is false’. After a month, his friends get the first letter written in blue ink: ‘Everything is wonderful here: stores are full, food is abundant, apartments are large and properly heated, movie theatres show films from the West, there are many beautiful girls ready for an affair – the only thing unavailable is red ink’. The point of the joke is that without the red ink, we lack the very language to articulate our reality. Paraphrasing Žižek, what this lack of red ink means is that all the main terms we use to designate the present situation – ‘productive consumer publics’, ‘informal economy and freedom’, ‘common resources’, etc. – are false terms, mystifying our perception of the situation instead of allowing us to think it. Before we offer solutions, we need the red ink.

### AT: Perm

#### All links are DAs to the perm

#### Cooption DA: No matter the intent of the perm it will end up footnoting the radicality of the alt — for example Occupy was a radical grassroots anticap movement but it ended up being coopted by capitalist elites.

#### The links proves mutual exclusivity – if we win they view COVID through a profit driven lens, they can’t be compatible with the anticapitalism of the alt.

#### The perm is severance of their representations – severance is a voting issue because it makes the aff a moving target which is unfair and kills neg strategy.

#### Evaluate the debate as competing methodologies/understandings of the world – this means the perm is incoherent if we aren’t evaluating competing policies.

#### No net benefit – we solve the AC because we solve the root cause– neoliberal corporations. Evaluate the perm debate through a risk analysis – if we win root cause claims, there’s no reason to risk the AC links hurting alt solvency.

### XT: FW

#### Weigh the K over the case-

#### Epistemology – the K indicts the knowledge production processes of the AC – they first have to win that their authors are understanding the problem through the correct lens before they can win any form of solvency, which makes the K a pre req to the case – that’s Hay and Rosamund.

#### Fiat is illusory – the plan never passes, so the only tangible impact is the orientation the judge chooses to forward in the academic space – you have a real world obligation to rid educational spaces of neoliberalism.

#### Plan focus is a capitalist move to innocence that attempts to displace their culpability for epistemic objectification by saying “uhhh that’s not in the plan text”—the plan text was a fraction of the 1AC—if we win that the aff produces capitalist scholarship, you cannot ethically justify voting for it because you are an educator, not a policymaker.

#### DON'T COP OUT—judges nowadays just disregard framework and let the aff get access to all their impacts. If we win our link arguments you shouldn't weigh their advantages not because of theory, but because their advantages aren't true.

## Voters

#### WEIGH THE CAP K FIRST- their solvency doesn’t even work and